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Abstract 
Glioblastoma Multiforme (GBM) is the most common primary brain malignancy and 
invariably fatal. Evidence has emerged showing human cytomegalovirus (HCMV) infection 
is present in GBM, providing a possible target for new immunotherapeutic agents. This thesis 
aims to examine the functional characteristics of T-cell responses to GBM, including HCMV-
specific T-Cells.  To examine the effects of exposure HCMV in patients with GBM an 80 
patient cohort was assessed.  No difference was seen between HCMV seropostive and 
seronegative patients with median progression free survival of 344 days vs. 348 days 
(p=0.453) and median overall survival s 719 days vs. 780 days (p=0.553). To further 
investigate HCMV immunity in GBM, gene microarray analysis was performed on CD8+ T-
cells and HCMV specific T-cells from GBM patients. Analysis of CD8+ T-cells in GBM 
patients showed down regulation of genes in two distinct subgroups related to effector 
function and the exhausted phenotype of T-cells usually seen in persistent virus infection. 
Included in this was significant up regulation of the co-inhibitory gene BTLA along with 
down regulation of the gene for co-stimulatory molecule LIGHT. These are both ligands of 
Herpes Virus Entry Mediator (HVEM) suggesting this may be an important pathway of 
immune suppression in GBM.  Flow Cytometry studies however failed to confirm differences 
in surface expression of these molecules in T-cells of GBM patients. HVEM was however 
seen to be expressed in tissue in a significant number of tumours examined by 
immunohistochemistry. Further studies are required to define the role of these pathways and 
their suitability for manipulation as a standalone therapy or adjunct to other 
immunotherapeutic strategies. 
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Chapter 1: Introduction 
Glioblastoma Multiforme (GBM) is the most common primary brain malignancy in adults 
with an incidence of 3.15 per 100,000 in the United States [1]. It is characterised by an 
aggressive clinical course and is invariably fatal. Current “gold standard” therapy consists of 
maximal surgical debulking followed by radiotherapy and chemotherapy [2]. Therapy for 
recurrent tumours is limited to palliative resection and second line chemotherapeutic agents 
[3, 4]. Prognosis in GBM is remains uniformly poor with a median survival after “gold 
standard” therapy of 14.6 months following diagnosis [5]. Given the limited success of 
current therapeutic strategies there has been considerable effort into establishing a better 
understanding of GBM biology and exploring potential therapeutic pathways such as 
immunotherapy. In recent years significant evidence has emerged showing that  human 
cytomegalovirus (HCMV) is present in GBM and that it plays a oncomodulatory role [6]. The 
presence of HCMV infection in GBM is not only a possible factor in tumour growth but also 
provides  potential antigen targets for novel therapeutic strategies such as immunotherapy.. 
 
Our laboratory is currently trialling HCMV specific adoptive T-cell transfer in GBM patients. 
Specific adoptive cell transfer (ACT) refers to tumour specific therapy with cytotoxic T-Cells 
harvested from a tumour bearing host. These tumour specific autologous cells then undergo 
ex vivo expansion, activation and are transferred back to the patient [7]. This technique 
provides a passive immunotherapy to give a tumour specific response. The benefits of this 
approach are the ability to give large numbers of cells that have a high specificity for tumour 
antigens and to bypass the immunosuppressive tumour microenvironment [8]. It also gives an 
opportunity for selection of effector cells that show the best anti-tumour activity away from 
the in vivo environment and effects of physiological or pathophysiological control [9].  
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Fig 1.1: Adoptive T-cell transfer: CD8+ T-Cells are isolated from peripheral blood samples 
of patients with recurrent GBM after standard treatments with surgery, radiotherapy and 
chemotherapy. These cells are then stimulated with CMV epitopes and IL2 ex-vivo then 
transferred back to the patient. (Figure modified from original: www.attack-cancer.org) 
 
Previous studies from this laboratory demonstrated that CMV seropositive GBM patients 
have circulating HCMV-specific T-cells at levels that are similar to healthy individuals; 
however, the majority of these cells are non-functional or display limited functionality [10]. 
The aim of this study is to better characterise the T-Cell response to GBM in order to identify 
factors which are acting to inhibit the host anti-tumour response. This information could be 
used to develop targets for manipulation that may potentiate immunotherapy, act as stand 
alone therapies or facilitate the ex vivo engineering of T-Cells to be better suited to adoptive 
T-Cell therapy.  
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1.1 GBM Biology 
Gliomas are tumours arising from the glial cells of the central nervous system, most 
commonly astrocytes, and are graded according to the World Health Organisation (WHO) 
into four grades based on histological characteristics [11]. GBM represents WHO grade IV. 
The peak incidence occurs between 45-75 years with a slight bias towards males. Typically 
these tumours occur in the sub-cortical white matter of the cerebral hemisphere however they 
may occur anywhere in the CNS. Histological examination shows characteristic pallisading 
necrosis and microvascular proliferation. Risk factors for GBM are uncertain but include 
ionising radiation and some genetic syndromes, however only 1-3% of GBM can be 
attributed to identifiable genetic conditions. GBM occur in two settings; as de novo tumours 
in usually older patients (primary) and in younger patients with a previous lower grade 
astrocytoma (secondary). On a molecular level primary and secondary GBM have subtle 
differences but tend to converge on the same pathways [11]. As an example secondary GBM 
tends to have mutations of the tumour suppressor gene p53 whereas primary GBM are more 
likely to show amplification of the MDM2 gene which codes for a suppressor of p53. An 
important molecular marker of secondary vs. primary GBM is mutation of isocitrate 
dehydrogenase 1 and 2 (IDH1 & IDH2) which is found in more than 80% of  secondary 
GBM but only few primary GBM [12].  This suggests a different genetic pathway for 
primary and secondary tumours which may lead to different clinical courses. Common 
molecular lesions seen in GBM are activation of RAS and PI-3 kinase and inactivation of p53 
and Rb. These changes are seen in 80-90% of GBM.  
Just as GBM are characterised by cellular heterogeneity they also display a wide array of 
molecular changes and disruptions few of which have been fully defined [13] [14]. Studies of 
GBM tissue using gene expression analysis have led to further classification of GBM based 
on a molecular profile [13]. These sub-types are Proneural, Neural, Classical, and 
Mesenchymal. The Classical, Mesenchymal, and Proneural subtypes are defined by changes 
in gene expression of epidermal growth factor receptor (EGFR), neurofibromin 1 (NF1), and 
alpha-type platelet-derived growth factor receptor (PDGFRA) respectively. These subtypes 
appear to be of clinical relevance in that a more aggressive therapeutic strategy, defined as 
concurrent chemotherapy and radiotherapy or greater than three cycles of chemotherapy, has 
a greater benefit in the classical subtype but is of limited benefit in the proneural subtypes 
[14].  
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The traditional model of tumourigenesis involves a mutation in a single cell that then 
undergoes clonal expansion producing a tumour. The origin of this single cell mutation is 
controversial and in GBM there are two theories that compete and may overlap [15, 16]. 
Firstly the “de-differentiation theory” proposes a series of changes conveying the hallmarks 
of cancer such as resistance to apoptosis onto mature astrocytes transforming them into 
malignant cells.  The alternate theory involves quiescent stem cells that lie dormant until a 
triggering event leads to development of a tumour. These sub-populations are then believed 
to persist within the tumour that possessing tumourogenic capability driving the malignant 
characteristics of GBM, with the rest of the cells acting as non-tumour initiating constituents 
of the tumour. This hypothesis developed from the observation that subgroups of cells in 
GBM have the characteristics of stem cells in that they can regenerate and differentiate into 
different cell types (astrocytes and neurons). When these cells are injected into 
immunocompromised animals they generate tumours [17]. These are referred to as glioma 
Cancer Stem Cells (gCSC). A tremendous amount of research is now directed at tumour stem 
cells to understand how they may act in resistance to standard therapy and be targets for new 
agents. gCSC’s have been shown to have resistance to chemotherapy and radiotherapy when 
compared to other GBM cells and this may underlie the relative resistance of GBM to 
conventional therapies [18]. In addition these stem cells have immunosuppressive activity via 
cytokines such as soluble colony-stimulating factor (sCSF-1), Transforming growth factor 
beta 1 (TGF-β1), and macrophage inhibitory cytokine-1. They also induce an M2 phenotype 
in microglia inducing immunosuppressive IL-10 and inhibiting proliferation of T-cells [19]. 
Interestingly recent studies have shown that HCMV shows tropism for gCSC’s and 
macrophages. The production of HCMV IL-10 by these cells then feeds forward by 
promoting monocytes to adopt a tumorigenic phenotype and express angiogenic vascular 
endothelial growth factor (VEGF), immunosuppressive TGF-β1 and promote gCSC 
migration [20].  
 
1.2. GBM Treatment and survival 
Surgical resection of GBM has proven to be non curative. However surgery remains a 
mainstay of treatment, the rationale being three-fold; to obtain tissue for histological 
diagnosis, relieve mass effect and reduce tumour load.  Adjuvant external beam radiotherapy 
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to a dose of 60-65 Gray is given as standard treatment with concurrent chemotherapy[21]. 
Factors that have been shown to be predictive of longer survival are extent of surgery, age 
<60yrs and Karnofsky grading at diagnosis [22, 23]. 
The biggest improvement in terms of survival in recent years has been the introduction of 
Temozolomide chemotherapy [2]. Temozolomide causes cell death by apoptosis via 
methylation of DNA at the N-7 or O-6 guanine residues, inducing cell cycle arrest at G2/M-
phase [24].The effectiveness of Temozolomide is variable with one factor being the silencing 
of MGMT gene expression [25]. MGMT is a critical enzyme for repair of DNA and its loss 
potentiates the chemotherapeutically induced DNA damage. Older chemotherapy strategies 
such as Lomustine (CCNU) or the  Procarbazine, Vincristine (PCV) regime have been 
superseded in recent years and are now reserved for second line therapy [4]. Bevacizumab 
(Avastin®, Genentech) is new chemotherapeutic agent approved by the US FDA for 
recurrent GBM. It is a monoclonal antibody against VEGF and thus acts as an inhibitor of 
angiogenesis [26]. The effectiveness of this drug on overall survival in GBM is unproven [27, 
28]. Other treatments that have been recently evaluated for effectiveness include intra-tumour 
placement of 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) wafers (Gliadel®, Arbor 
Pharmaceuticals). This has shown promising results in terms of survival but concerns persist 
regarding its toxicity profile preventing widespread adoption in clinical practice [29]. 
Despite improved understanding of GBM biology and new treatment strategies overall 
prognosis remains dismal with only limited therapeutic options therefore further advances 
both clinical and scientific are needed.  
 
1.3. HCMV Biology 
HCMV infection is common. It has prevalence of 40 to 100% depending on geographic and 
socio-economic factors [30]. Viral transmission has been reported via saliva, sexual contact, 
breast milk and placental transfer; as well as blood transfusions and solid organ or 
hematopoietic stem cell transplantation [31]. Primary HCMV infection in an 
immunocompetent host is normally asymptomatic, occasionally presenting with malaise, 
headache and fever [32, 33]. Uncommon signs and symptoms include tonsillopharyngitis, 
lymphadenopathy or splenomegaly. Rare serious complications include ulcerative colitis, 
hepatitis, pneumonitis, meningitis, myocarditis and Guillian-Barre syndrome [34]. 
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In contrast to the mild disease in adults HCMV is the leading infectious cause of 
neurodevelopment defects and deafness in congenital infection. Primary infection in the 1
st
 
Trimester of pregnancy has a 40% risk of transmission.  10-15% neonates affected will 
display symptoms including pneumonia, hepatitis, chorioretinitis, growth retardation, central 
nervous system (CNS) damage and microcephaly.  This systemic infection is known as 
‘cytomegalic inclusion disease’ and is fatal in 20-30% of symptomatic cases, often results in 
neurological and visual impairment [35-37]. 
HCMV disease in adults has become increasingly important due to the rise in number of 
immunocompromised hosts resulting from the acquired immunodeficiency disease 
syndrome (AIDS) epidemic and immune compromising therapies such as organ and bone 
marrow transplantation and cancer chemotherapy [37]. Reactivation or primary infection in 
immunocompromised individuals can range from an asymptomatic viremia to fatal CMV 
syndrome and tissue-invasive disease [33]. Severity of disease correlates to immune 
dysfunction with  worse disease seen in allogeneic bone marrow or stem cell transplant 
recipients and AIDS patients with low CD4
+
 counts [38].  
HCMV is also known as ubiquitous beta human herpes virus type-five (HHV-5) and is the 
largest of the known human herpes viruses. It has a genome that spans 235 kilo bases 
encoding 165 genes controlling various functions. The HCMV virion measures 200-300 
nanometres. It consists of a DNA core surrounded by an icosahedral nuclear capisd and 
proteinaceous matrix. This is in turn enclosed by a lipid bilayer envelope containing viral 
glycoproteins [32, 39]. HCMV is known to infect fibroblasts, endothelial cells, epithelial 
cells, monocytes, macrophages, smooth muscle cells, stromal cells, neutrophils, hepatocytes 
and neuronal cells in vivo [40]. This broad range of susceptible cell types results in active 
infection impacting many organs systems in an immunocompromised host.  In the brain in 
vitro studies revealed complete permissiveness to HCMV of neuronal cell lines and 
undifferentiated glial cell lines from astrocytomas, but varying permissiveness to astrocytes, 
and higher differentiated glial lines from glioblastomas [41]. 
Replication of HCMV after entry to the cell is slow with a cycle of 48-72hrs  compared to 
other herpesvirus [42]. Cell entry is achieved by envelope fusion or endocytosis to host cell 
membrane and nucleocapsid release into cytoplasm.  The nucleocapisd is then uncoated in 
the nucleus and the viral DNA released to be transcribed by host RNA polymerase.  Post 
infection protein synthesis progresses in a sequential pattern typical of herpesviruses with 
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immediate early (IE); 0-2hrs, delayed early; 24hrs, and late; >24hrs [43]. The replicated 
genomes form concatemers with genomic inversions, then are packaged in empty capsids 
[44].  HCMV gene expression is further regulated, prior to complete virion production, at 
posttranscriptional, translational and posttranslational levels [16]. As virions exit from the 
cell, they acquire mature envelope from the Golgi membrane. This budding from the Golgi 
membrane causes cytoplasmic inclusion bodies which are characteristic of HCMV infection.  
Of the virions produced in this manner only 1% of are infectious, the rest consist largely of 
protein or are enveloped particles lacking genomes [32]. 
 
Latency and Reactivation 
One characteristic feature of all herpesvirus is persistence of the virus post primary infection 
in a quiescent non-replicating state. This latent state of viral infection persists for the lifetime 
of the host with periods of reactivation [45]. An important distinction must be made between 
true  latency in which the viral genome is maintained in the host cell with minimal or non-
detectable gene expression as opposed with persistent low level replication and shedding of 
infectious viral particles resulting in minimal cytopathy and long term infection [46]. 
While lytic HCMV infection can affect large numbers of cells, those which support latent 
infection are more select. Important sites of true latency of HCMV are monocytes in 
peripheral blood, hematopoietic myeloid progenitor cells CD34+ and CD33+ granulocyte-
macrophage progenitors. CD34+ bone marrow cells, and immature dendritic cells [47]. Blood 
vessel endothelial cells are also thought to be significant reservoir of HCMV replication, 
likely to be a site of persistent infection with low grade shedding rather than true latency [48].  
Latency is induced by disrupting replication via repression of the major immediate early 
promoter (MIEP) and expression of a latency specific subset of viral genes [49].  These result 
in signal modulation, restricted viral gene expression, and immune evasion. Reactivation of 
HCMV is requires the reversal of those factors inducing latency in response to inflammatory 
stress. TNF-α induced by inflammation in turn induces transcription factors NFκβ, API and 
CRE which bind to the MIEP causing reactivation [50]. Chronic inflammation triggers 
reactivation via stress induced catecholamines and pro-inflammatory prostaglandins [33]. 
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1.4. Tumour induced Immune Response and the CNS 
Tumours elicit an immune response primarily through CD8+ cytotoxic T-cells. These T-cells 
are activated by antigen expressed by the tumour in the form of over expressed or mutated 
self proteins, or tumour antigens generated by oncogenic viruses.  While there is little 
evidence that antibodies have a major anti-tumour role there is a known role for NK cells and 
macrophages in the tumour associated immune response. The protective value of this immune 
response in prevention of tumours is shown by the fact that immunodeficient hosts have 
higher rates of cancer.  Most cancers occur in immunocompetent hosts therefore tumours 
must have immunosurveillance escape mechanisms. Several mechanisms have been 
identified such as selective outgrowth of antigen-negative variants, loss of MHC expression, 
loss of co-stimulation required for T-Cell activation, local immunosuppression, antigen 
masking and apoptosis of cytotoxic T –cells.  
Since the observation that GBM patients who develop a post operative infection survive 
longer than those without there has been interest in the relationship between the immune 
response and the brain and brain tumours [51]. The brain has traditionally been thought to 
enjoy an immunologically privileged position due to a number of features unique to the CNS 
namely the blood-brain barrier, absence of lymphatics, immunoregulatory factors and lack of 
MHC expression in normal CNS cells. 
This was believed to provide a mechanism by which the brain was protected from potentially 
damaging inflammatory processes which occur hand in hand with an immune response. This 
would mitigate the potential for cerebral oedema and its neurological sequelae.  This 
previously widespread concept of immune privilege for the CNS has been largely refuted by 
the discovery that activated peripheral T-cells along with antibodies are able to cross the 
blood-brain barrier and furthermore antigen specific T-cells are able to proliferate and 
acquire effector function in the CNS however these are likely to have altered functional 
ability [52-54].  Within the brain T-cells are rare, activation is required for T-cell entry into 
the CNS but this need not be antigen specific [54].  
In the CNS microglia act as macrophages by expressing MHC class II antigen along with co-
stimulatory molecules allowing T-cell activation, demonstrating that the CNS is in a dynamic 
state with the peripheral nervous system [55]. Whilst the normal CNS has been shown to be 
immunocompetent it has long been recognised that patients harbouring GBM have impaired 
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immune response [56, 57]. This immunosuppression in the GBM patient is due to a number 
of mechanisms both systemic and local many related to T-cell function. The systemic  
impaired immune response in GBM patients can been seen at a gross level with leucopoenia 
on peripheral blood counts which appears to improve following cytoreductive surgery and 
decline again at recurrence [58, 59]. In terms of T-cell function systemic responses are 
inhibited through increased circulating Tregs [60]. Within the tumour micro environment 
inhibitory factors include expression of Fas ligand by the tumour resulting in T-cell 
apoptosis, high levels of infiltrating Tregs, and an overall inhibitory cytokine milieu.[61] 
Simple physical factors such as hypoxia in necrotic tissue also play a role in T-cell 
dysfunction in GBM [62]. 
The poor immune response to GBM can in part be attributed to the weak immunogenicity of 
the tumour-associated anti-gens (TAA). TAA’s in GBM are classified in 4 ways: (i) those 
antigens expressed due to translocations or mutations such as EGFRvIII, (ii) antigens from 
genes  derived from cancer-germ lines such as melanoma associated antigen, (iii) over 
expressed genes such as human epidermal growth factor receptor 2 (HER2), (iv) antigens 
from viruses such as the CMV antigens IE1 and pp65 [63]. These antigens are in their own 
right weakly immunoreactive but are still able to act as targets for immunotherapy. One such 
specific antigen targeted in GBM patients is the EGFR. These are regulators of cell migration 
and survival and there gene has been shown to be amplified in GBM, specifically EGFRvIII 
has only been seen in GBM [64, 65]. A study by Choi et al used  Bio-specific antibodies 
(bscAbs), specifically bio-specific T-cell engager (BiTE) subclass, to effectively redirect T 
cells against GBM in mice [66]. They targeted a mutation of EGFRvIII, and found significant 
survival benefit with a cure rate 75%. This demonstrates that with correct antigen targeting 
the T-Cell response can have a very effective anti-tumour effect. 
 
T-Cell Dysfunction in GBM 
The T-Cell dysfunction seen in GBM patients is likely a result of overlapping mechanisms of 
anergy, exhaustion, senescence and stemness (see fig 1.3). 
T-cell Anergy refers to the state in which lymphocytes are functionally inactivated after 
exposure to an antigen but persist in a hypo responsive state for a period of time [67]. T-Cell 
activation requires both MHC and co-stimulatory molecule signals. Low stimulatory and/or 
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high inhibitory signal will result in anergy [68]. This is believed to be a mechanism for 
avoiding autoimmune disease. In GBM patients profiling of T-cells has shown decreased 
levels of mRNA transcripts for genes which are important for T-cell function and in 
particular the process of TCR binding and activation along with the subsequent intracellular 
signalling [69]. Such improper TCR signal transduction is thought to be important in the 
development of T-Cell anergy [70]. 
T-Cell exhaustion refers to a state of poor function with reduced proliferation, cytotoxicity 
and cytokine secretion in response to chronic stimulation from inflammation, chronic 
infection or tumour antigen [71]. The mechanism of exhaustion is the focus of great interest 
currently. A number of negative co-stimulatory factors have now been identified which may 
induce a state of T-cell exhaustion [70]. These mechanisms likely evolved to limit tissue 
damage post- infection but have been subverted by disease states. This was first observed in 
chronic lymphocytic choriomeningitis (LCMV) in mice and has been shown in a number of 
chronic viral infective states such as HIV, hepatitis B and C.  The mechanism has been 
localised to a number of regulatory molecules shown in fig 1.3. T-Cell exhaustion via these 
pathways has also been seen in a number of cancers [72, 73].  There are now a multiple of 
studies examining the role of the co-stimulatory factors such as PD-1 and CTLA-4  in the 
setting of GBM, these studies have shown that these molecules are expressed in GBM and 
may have direct effects on T cell function with potential clinical applications [74, 75].  
T-cell senescence is the result of physiological processes as cells reach the end of their life 
span.  It is characterised by telomere shortening, cell cycle arrest and phenotypic changes. A 
subpopulation of senescence T-cells have been identified in a number of cancers however 
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Figure 1.2: Characteristics of anergic, exhausted, senescent and stem-like T-cells. T-cells 
can exisit in each of these states due to interactions with the receptors and subsequent 
intracellular processes shown in this diagram Anergic T-cells are non-responsive with low 
production of IL-2 as a mechanism of tolerance. Exhausted T-cells accumulate in chronic 
disease in an unresponsive long lived state.  Senescent T-cells accumulate due to aging or 
chronic infection. Stem-like T-cells are quiescent, self renewing but long lived cells. 
(Modified from: Crespo et al. T Cell anergy, exhaustion, senescence and stemness. Current 
Opinion in Immunology 25:214-221. 2013) 
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there is no direct evidence of this mechanism being active against mature T-cells within 
tumours. 
The concept of “stem-like memory T-cells” refers to the ability of this cell population to self 
renew and generate more differentiated memory T-cells. This concept has been supported by 
evidence in mouse models that central memory T-cells are arrested pre-differentiation and 
then after a second antigen exposure can generate effector T-cells [76]. This has also been 
shown in tumour associated Th17 cells [77].  There is theoretical potential to manipulate 
these stem like cells for therapeutic applications. 
 
 Immunomodulatory Molecules 
T-cell function is modulated by interaction with co-signalling molecules. There are two 
superfamilies of co-signalling molecules, tumour necrosis factor receptor (TNFR) family and 
immunoglobulin (Ig) superfamily. Activation of T-cells requires co-stimulation via receptor 
CD28, similarly there are a number of negative co-stimulatory factors now identified which 
inhibit T-cell function.  These mechanisms likely evolved to avoid autoimmunity and limit 
tissue damage post infection but have been subverted by disease states. A number of 
regulatory molecules such as PD-1, Tim-3, and LAG3 have been identified and are of 
relevance in anti-tumour immunity [78]. These various inhibitory molecules can potentially 
be blocked by antibodies and likewise stimulatory molecules could be activated by agonistic 
antibodies as shown in fig 1.3. Manipulation of the immune system via these pathways has 
been likened to control of a car using break (co-inhibitory molecules), clutch (blocking anti-
bodies) and accelerator (co-stimulatory molecules). 
T-cell inhibition via these pathways has been seen in a number of cancers and manipulating 
these pathways by targeting molecules such as CTLA-4 with the FDA approved drug 
Ipilimumab (Yervoy; Bristol-Myers Squibb, NY, USA) have led to great interest in 
evaluating the role of them in various diseases such as GBM.   
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Fig 1.3: Examples of Co-inhibitory and co-stimulatory molecules. These molecules can 
potentially be stimulated or blocked by antibodies to manipulate T-Cell activation. (Modified 
from Reardon et al. An update on vaccine therapy and other immunotherapeutic approaches 
for Glioblastoma. Expert Rev. Vaccines 12(6), 597-615. 2013 )  
 
  
1.5. Tumour Microenvironment Immunosuppression  
GBM  has the ability to evade immunosurveillance, create an immunosuppressive micro 
environment and subvert the immune response to promote tumour growth [61]. Creating an 
immunosuppressive microenvironment within the GBM appears to be an important factor in 
its biology. Tumour infiltrating lymphocytes (TIL) have been shown to be present in GBM,  
providing a survival benefit and demonstrating the presence of some anti-tumour immune 
response [79].  Despite the presence of these cells an immune response in GBM fails, due to a 
range of mechanisms active within the tumour microenvironment [80]. GBM patients have 
impaired anti-tumour immune response through multiple mechanisms and blockade or 
modification of these inhibitory pathways provides an attractive therapeutic strategy. 
Examples of these mechanisms are immunosuppressive microglia; T-regulatory cells (Tregs); 
cytokine secretion patterns and the signal transducer STAT3.  
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Microglia 
Within the GBM microenvironment cytotoxic T-Cell function is suppressed by dysfunction 
of microglia. Microglia have been shown to be the main MHC II presenting cells in the CNS 
as astrocytes express only low levels of MHC II molecules [81].  Within GBM tissue 
microglia has impaired APC function and they may suppress the effect of cytotoxic T-Cells 
through expression tumour promoting chemokines.  
In the setting of GBM the MHC class II expressing  microglia may be hi-jacked into 
secreting pro-glioma factors such as monocyte chemo attractant protein 1 (MCP-1) [82]. 
Studies have shown that this is a powerful tumour promoter with MCP-1 transfected rats 
displaying a significant reduction in survival. In the rats there was also an increase in 
microglia infiltration suggesting they further promote tumour growth [83].  
 
Tregs 
An important mechanism by which GBM subverts the immune response is via regulatory T-
Cells (Tregs). Tregs are believed to prevent auto-immunity by controlling the proliferation of 
auto reactive T-cells. Tregs inhibit expression of MHC II molecules, CD40, CD80, and CD86 
through inhibition of IL-2, IFN-γ and increasing production of the TH2 class of cytokines. 
This results in suppression of antigen presentation in monocytes and macrophages. Tregs can 
be identified by the expression of forkhead box P3 (FoxP3) which is up regulated in GBM 
tissue compared to both autologous peripheral blood and healthy controls [84, 85]. In GBM 
tissue FoxP3 expression has been seen to be correlated to WHO tumour grade[86]. 
Furthermore serum Tregs are seen at higher proportions in GBM patients compared to normal 
controls thus contributing to the systemic immunosuppression in these patients [87]. 
Depletion of Tregs in a mouse model has been shown to provide an anti-tumour effect with 
improved survival however human data has not been correlated to survival [60, 86]. 
Excitingly for potential therapeutic applications in vivo depletion of these Tregs cells has 
potentiated the effects of adoptively transferred T-cells [88]. In addition the 
chemotherapeutic drug Temozolomide which is usually given concurrently with 
immunotherapy, is thought to inhibit Tregs trafficking possibly contributing to its clinical 
effectiveness [89]. 
  
Cytokines 
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As a GBM progresses a series of immune suppressive changes take place in terms of cytokine 
secretion. There is reduced expression of IL-12, IFN-γ and TNF-α along with increased 
expression of IL-4, IL-5, Il-6, IL-10 and immunosuppressive protein TGF-β2 and 
prostaglandin E2 (PG E2) [90]. These act on multiple pathways to affect immune function 
with the effect more pronounced on CD4+ than CD8+ T-cells [91]. An example is the 
proliferation of T-cells and down regulation of monocyte MHC II in response to increased 
tumour secretion of  IL-10 [92].  
Blockade of individual cytokines has shown some possible therapeutic benefit. Anti-sense 
oligonucleotide targeted at TGF-β2 as shown to provide a survival benefit compared to 
standard chemotherapy regimes in phase I/II trials but phase II trials were stopped due to 
slow subject recruitment [93, 94].   
Conversely cytokines can be directed against the tumour as a form of immunotherapy. An 
example of which is the strategy of “arming” oncolytic viruses such as HSV with cytokines 
in particular IL12 to potentiate their anti-tumour effect [95].Given the multiple pathways 
contributing to the immunosuppressive environment and the general cytokine milieu it 
becomes difficult to identify the relative significance of each. It is therefore unlikely that 
suppression or potentiation of a single cytokine pathway will have significant therapeutic 
effect. Blockade of common pathways or multiple cytokines would be more likely to confer a 
clinical benefit. 
 
STAT-3 
Signal transducer and activator of transcription type 3 (STAT-3) is an important molecular 
switch for tumour cells to avoid immune detection as well as enabling proliferation, 
promotion of angiogenesis and resistance to apoptosis. STAT-3 is controlled by growth factor 
receptor tyrosine kinases, cytokines and G-protein receptors which are also among the most 
commonly activated oncogenic proteins. An example in GBM is phosphorylation of STAT-3 
by EGFRvIII [96].  
STAT-3 activity has also been shown to be a key regulator of systemic immune function in 
the tumour setting.  STAT-3 activity is induced within the tumour microenvironment and 
modulates the activity of tumour infiltrating immune cells, reducing cytotoxicity of NK cells 
and neutrophils [97]. In DC’s STAT-3 activity down regulates expression of MHC class II, 
CD80, CD86 and IL-12 blocking their ability to stimulate T-Cells. These effects have been 
reversed with STAT-3 ablation in hematopoietic cells in mice resulting in marked 
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improvement in the host anti-tumour immune response [97].  In microglia isolated from 
GBM patients blockade of  STAT-3 induced up regulation of co-stimulatory molecules, 
promoted secreting of proinflammatory cytokines and induced T-Cell proliferation and 
activation [98]. 
 
1.6. HCMV in GBM 
Viruses have been implicated in a number of cancers, for example the commonly known 
associations of cervical carcinoma with human papilloma virus (HPV) and hepatocellular 
carcinoma with Hepatitis B & C. There are many more examples with varying mechanism of 
oncogenesis but the principle of virus leading to malignancy is widely accepted [99]. 
A number of viruses have been implicated in brain tumours and studies have suggested that 
exposure to common viruses resulting in diseases such as chickenpox or shingles may have 
an effect on development of glioma in later life [100]. Exposure to contaminated polio 
vaccine had been suggested to increase likelihood of glioma and this was experimentally 
supported in hamsters by induction of tumours with this virus (simian virus 40) [101]. This 
theory has not been conclusively borne out by epidemiological studies.  
In contrast Wrensch has reported an inverse relationship between the presence of Varicella-
zoster viral infection and rate of GBM [102]. This study also reported that GBM patients 
were less likely to have anti-bodies against Epstein-Barr virus (EBV) [102, 103]. 
Interestingly an increased likelihood of antibodies against herpes simplex virus (HSV) and 
HCMV in GBM patients compared with controls was seen.  
These studies have lead on to work establishing that HCMV is present in GBM and has 
triggered interest in its role in the disease and potential as a therapeutic target [6]. 
 
Evidence for HCMV in GBM 
The potential role of HCMV in GBM  has been controversial [6]. HCMV is a common herpes 
virus that infects 40-100% of the human population, in comparison to the prevalence of GBM 
at 0.0257% [104]. Foetal HCMV infection is the most common infective cause of hearing 
loss, mental retardation and birth defects. Infection in immunocompetent patients is usually 
subclinical and 40% of these occur within the first year of life. In immunocompromised 
patients symptoms may occur with fever, malaise and pneumonia the most common. Once 
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infected the HCMV is never cleared by the host leading to lifelong viral persistence. 
Reactivation in immunocompetent individuals elicits an immune response by innate and 
adaptive pathways. 
HCMV infection in the setting of  GBM was first raised by Cobbs et al [105].  In his study 
they found immunohistochemical evidence of expression of the HCMV specific IE1-72 
(immediate early) protein in all 27 of 27 gliomas examined, compared to none in brain 
samples taken from controls (meningiomas, Alzheimer’s patient, normal brain). This 
expression was limited to malignant tissue and not seen in surrounding brain or areas of 
necrosis within the specimens. Further in-situ hybridisation (ISH) techniques were then used 
to show the presence of HCMV immediate-early gene mRNA in these tumours. Again 
endothelial tumour cells were positive along with some vascular smooth muscle whereas 
controls and surrounding normal brain were not. These findings were not initially reproduced 
and studies were published showing both presence and absence of HCMV in glioma tissue 
[106-108]. Scheurer et al published a study in 2008 stressing the technical considerations 
when extracting from paraffin-embedded tissue and showing a 100% rate of IE-1 protein in 
21 cases of GBM using immunohistochemical methods [109]. These findings were supported 
by ISH and are consistent with Cobb’s findings. Ongoing studies have shown the presence of 
HCMV proteins US28, pp65, gB, IL-10 and pp28 along with the most commonly studied IE-
1 [20, 105, 107, 109-112] 
As described above there is now strong evidence that HCMV viral genes are expressed in 
GBM. If HCMV infection is present in GBM it could exist in either a lytic or latent state. In 
the lytic state viral replication is driven by the IE genes regulating transcription of host and 
viral genes and inhibiting apoptosis resulting in a cytopathic effect.  Latency is characterised 
by lack of production of virions and absence of expression of the lytic genes such as IE-1.  
Currently the evidence points to HCMV in GBM existing in neither of these classical states. 
In GBM HCMV IE-1 expression is seen uniformly but there have been no published studies 
showing production of HCMV virions in GBM.  The human cytomegalovirus and glioma 
symposium consensus was that HCMV acts in a similar model that proposed for 
cardiovascular disease [6]. In this model, persistent HCMV infection of vascular endothelial 
cells resulted in viral expression without a cytopathic effect. This results in production of 
cytokines and renin and thus hypertension [113]. In a tumour this chronic infection is 
proposed to lead to expression of HCMV genes that induce production of cytokines that may 
contribute to oncogenesis or interact with the cell cycle to cause disruption to normal 
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regulatory mechanisms. This is in contrast to the example of HPV which leads to direct 
malignant transformation of the infected cells.  
 
 
 
Oncomodulatory Role of HCMV in GBM 
For a virus to be considered oncogenic they should show certain features that are lacking in 
HCMV infection, such as sustained expression of oncoproteins and integration into the host 
genome. Viruses with known oncogenic properties such as human papilloma virus (HPV) and 
Hepatitis B virus display these characteristics, HCMV does not. Cinatl et al showed that in 
neuroblastoma cells lines HCMV infection while not responsible for the malignant 
transformation produced phenotypic changes such as increased expression of oncoproteins 
and decreased expression of tyrosine hydroxylase and dopamine beta hydroxylase. They 
postulated that the HCMV thus acts as a co-factor in the development of a fully malignant 
cell phenotype [114]. This oncomodulatory role for HCMV fits with the known molecular 
biology of  HCMV [115]. HCMV activity has been shown to affect pathways altering cell 
physiology a manner consistent with the 10 hallmarks of cancer which are sustained 
proliferative signalling, Evasion of growth suppression, Invasion and metastasis, Immortality, 
Angiogenesis, Resistance to cell death, Deregulation of cellular energetics,  Avoidance of 
immune detection, Genome instability and Inflammation [53][116].  
In Vivo animal data supports this oncomodulatory effect of CMV.  In one such study 
transgenic (Mut3) mice engineered to generate gliomas were perinatally infected with murine 
CMV (mCMV) [117]. These mCMV mice showed a markedly shortened median survival 
time and tumours with a more aggressive behaviour. Human data showed a relationship 
between CMV antigen expression and survival in GBM patients. A total of 75 patients with 
GBM, 74 of who were HCMV positive were studied. Using immunohistochemistry and in-
situ hybridization to  assess and grade viral expression they showed high levels of expression 
were associated with a shortening of survival time by 20mths compared with low levels of 
expression [118]. Patients with less than 25% CMV infected tumour cells at diagnosis 
showed a 2 year survival benefit compared with those with 25-90% CMV infected tumour 
cells. Time to tumour progression was 22 vs. 9 months and at 24 months, 60% of the patients 
with low-grade CMV infection were alive vs. 20% with high grade infection. However the  
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link between expression of HCMV in GBM tissue and poorer prognosis has not been seen 
consistently and remains controversial [119].  
Given the recent interest in CMV in GBM a meeting of experts in the field was held to 
produce a consensus report. The outcome provides a summary of the “state of play” for the 
role of CMV in GBM and concluded with four key points[6]. 
1. “there is sufficient evidence to conclude that HCMV sequences and viral gene 
expression exist in most, if not all, malignant gliomas” 
2. “there is sufficient evidence to support the hypothesis that HCMV could modulate the 
malignant phenotype in Glioblastoma” 
3. “HCMV could serve as a novel target for a variety of therapeutic strategies” 
4. 2 areas of research were suggested 
a. Epidemiological study to determine why only small minority of latent HCMV 
infection evolve into GBM 
b. “elaboration of how HCMV contributes to glioma malignancy could identify 
novel therapeutic targets” 
Mechanisms of Oncomodulation 
As discussed the idea that HCMV is active in GBM in an oncomodulatory role can be 
examined in relation to each of the hallmarks of cancer described previously and summarised 
in Table 1. 
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Table 1.1: HCMV biology and cancer hallmarks (from Dziurzynski et al, Consensus on the 
role of human cytomegalovirus in Glioblastoma.  Neuro-oncology. 14(3): 246-255, 2012)  
Hallmark HCMV  Activity Protein Involved 
Sustaining 
Proliferative Signalling 
Induces cell cycle progression to S phase 
Induces expression of E2F genes 
Phosphorylates Rb 
IE2 
pp71 
UL97 
Evading Growth 
Suppressors 
Activates EGDFR 
Dysregulation of Cyclin E expression 
Inhibits p53 degradation 
Decreases levels of p21 
Induces expression of p%3 
Binds to p53 
HCMV infection 
IE1 
mtrll 
Activating Invasion 
and metastasis 
Activation of RhoA dependant motility of 
U373 cells 
Activates smooth muscle cells 
US28 
Enabling Relative 
Immortality 
Activation of telomerase IE1 
Inducing angiogenesis Induction of VEGF expression 
Induction of IL-8 
US28 
IE1 
Resisting Cell Death Inhibits apoptosis 
Activates PI3-K/Akt pathway 
IE1 
IE2 vMIA, vICA 
Avoiding immune 
destruction 
Production of homologs to 
immunosuppressive cytokines 
Inhibits expression of MCH 1 
Intracellular retention of NKG2D 
Induces expression of TGF-α1 
HCMV IL-10 
 
US2 
UL16 
IE2 
Genome Instability and 
Mutation 
Chromosome damage 
Inhibits DNA damage repair 
Increases mutation frequency 
Induces chromosome aberrations in cell lines 
Unidentified 
protein 
HCMV infection 
pp65 and pp71 
IE1, UL76 
Tumour Promoting 
Inflammation 
Induces production of RANTES, fraktalkine, 
MCP-1 
NF-γβ activation & IL-6 production 
HCMV infection 
 
US28 
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Sustaining Proliferative Signalling, Evading Growth Suppressors and Resisting Cell Death 
Disruption of cell cycle regulation by p53 and Rb is an important hallmark of all cancers and 
of proven importance in GBM.  HCMV related proteins, pp71 and UL97, are able both to 
degrade and phosphorylate these tumour suppressors [94, 120]. This has not been specifically 
reported in GBM cells as yet.  Persistent expression of IE1 has been evaluated in a number of 
cells lines, this was shown to affect cellular proliferation differently, some showing increase 
and other unchanged or decreased potentially via the MAPK and AKT pathway [121]. 
 
Activating Invasion and metastasis 
HCMV infection of GBM cells have been shown to phosphorylate focal adhesion kinase 
(FAK) Tyr397 [122]. This is a critical kinase for integrin-mediated migration and invasion 
and its expression correlated with invasiveness in many malignancies [123]. The activation of 
FAK by HCMV leads to increased extracellular matrix-dependent migration of GBM cells, 
which is not seen in normal astrocytes [122]. Furthermore HCMV has been shown to down 
regulate neural adhesion molecule (NCAM)  in neuroblastoma cells resulting in enhanced 
penetration through  the endothelium [124]. Through these mechanisms HCMV promotes 
invasion and metastasis. 
 
 Enabling Relative Immortality  
Avoidance of apoptosis and immortalization is critical to development of malignancy. 
HCMV has shown to convey resistance to apoptosis in fibroblast and neuroblastoma cells 
[125, 126].  Immortalization of cancer cells requires activation of telomerase by expression of 
the telomerase reverse transcriptase (hTERT) gene. After HCMV infection it has been shown 
that an important regular transcription factor specificity protein 1 (Sp1) binds to the hTERT 
promoter in fibroblast cells. In the same study GBM cells were examined and a direct 
correlation between HCMV immediate early antigen (IEA) and hTERT expression was seen 
in all samples tested [112, 127]. 
  
Angiogenesis 
Angiogenesis in GBM is thought to be promoted by HCMV infection via US28 pathway. US 
28 is a HCMV encoded G-protein coupled receptor which is expressed in early infection and 
has been isolated in GBM vascular endothelial cells. It binds certain chemokines and 
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persistent expression has shown to result in over expression of IL-6 and VEGF in certain cell 
lines [111]. When these cells were implanted into a nude mouse model, tumours resulted 
[128].  In addition US28 up regulates NF-kB which increases production of IL-6 which in 
turn activates STAT3 [111]. STAT 3 has effects both paracrine and autocrine, it is a key 
molecular component of tumourigenesis and suppression of immune response especially in 
GBM [129, 130]. STAT 3 induction in mouse neural progenitor cells has induced  increase 
VEGF expression, angiogenesis and GBM formation [131]. 
  
Genome Instability and Mutation 
HCMV induced damage to DNA repair mechanisms has been reported in the literature in a 
number of settings however not specifically in GBM [132]. Genomic instability due to 
HCMV infection as been shown by infection of human neural progenitor cells resulting in 
abnormalities of attachment, migration, loss of multipotency and down regulation of certain 
genes producing abnormal and premature differentiation [133]. Chronic infection of stem 
cells by HCMV has shown to produce specific chromosomal damage and therefore 
potentially oncogenic [134]. Virions from 3 strains of HCMV have been shown to cause 
breaks in chromosome 1 at 1q42 and a loss of this band has been seen in a small number of 
GBM samples [135]. In addition recent evidence has shown that HCMV infection can alter 
DNA methylation machinery. Response to chemotherapeutic agents such as Temozolomide 
has been linked to methylation status of key genes such MGMT, recent evidence point to the 
methylation status across the whole genome being of importance [25, 136].  
  
Avoiding immune destruction and Tumour Promoting Inflammation 
Immune evasion is a feature of both malignancy and HCMV virulence. The virus utilises 
several mechanisms to evade the host response and promote suppression of the immune 
system in the tumour microenvironment.  HCMV has been shown to latently infect bone 
marrow CD34+ cells in most healthy subjects [137]. The viral genome is then passed through 
the myeloid lineage until inflammation or immunosuppression leads to terminal 
differentiation into dendritic cells or mature macrophages and viral re-activation [47]. Within 
GBM it has been shown that macrophages and microglia, which make up a significant 
component of the microenvironment, are infected with HCMV [20]. HCMV infection creates 
a unique M1/M2 pattern in the macrophages and microglia [138]. The M1 phenotype is pro-
inflammatory via induction of cytokines such as IL-6 and TNF-γ. These cytokines have been 
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previously linked to oncogenesis in animal models of inflammatory induced cancer [139]. 
TNF-α may also promote reactivation of HCMV as seen in immunosuppressed patients [140]. 
The immunosuppressive M2 phenotype appears to be of particular importance in GBM. 
Glioma cancer stem cells (gCSC’s) produce HCMV IL-10 which is a homolog of human IL-
10 which is an immunosuppressive cytokine promoting the M2 phenotype [19]. This suggests 
a feed-forward mechanism whereby HCMV induces a M2 phenotype that stimulates 
migration of gCSC’s via increased VGEF and TGF-γ.  
The evidence outlined above demonstrates some of the potential pathways by which HCMV 
acts as an oncomodulatory virus in GBM rather than a true oncogenic virus.  
1.9. Immunotherapy in GBM 
Despite many promising therapeutic strategies there has been little change in outcomes for 
patients with GBM prior to the introduction of Temozolomide [141]. Immunotherapy is an 
attempt to manipulate or augment the patients’ immune system to better identify tumour 
antigens and then destroy tumour cells [142]. Immunotherapy for GBM has been studied 
since the 1950’s and 60’s with Mahaley’s work using monoclonal anti-bodies in CNS 
tumours [57]. Initial trials of therapeutic agents have until recently been limited to early 
phase trials delivered to patients with advanced disease, and while proving safety and 
tolerability, gave only limited clinical benefit, if any [143].   It is known that  CD8+ T-cell 
infiltration of GBM tissue is associated with prolonged outcome showing that an improved 
immune response can have clinical benefit [144]. In other types of cancer immunotherapy is 
more established. The United States Food and Drug Administration (FDA) has approved 
interferon alpha, interleukin-2 (IL-2) and  the CTLA4 anti-body Ipilimumab for melanoma 
and Sipuleucel-T (Provenge) for metastatic prostate cancer [145, 146]. Immunotheraputic 
approaches to GBM can be classified into four types: active, passive, adoptive and 
immunmodulatory. Active strategies involve direct challenge to the immune system with 
tumour specific antigens typically as a vaccine. Passive strategies involve targeting tumour 
antigen using effector molecules such as antibodies. Adoptive therapy involves harvesting 
cells from the host and manipulating them ex vivo prior to returning them to the patient. 
Immunomodulatory strategies involve manipulation of co-inhibitory and co-stimulatory 
molecules.  
The strategies currently showing the most promise for GBM are vaccination and adoptive cell 
strategies. 
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Vaccination 
Dendritic cells pulsed with tumour lysates is a promising vaccination strategy for GBM. This 
approach ensures immunogenicity against many tumour antigens and potentially allows for 
therapy tailored to each individual patient. As with many immunotherapies there remain the 
problems of delay whilst the vaccine is prepared and the risk of autoimmune reactions. In 
addition this approach requires tumour samples thus surgery which may not be feasible for all 
patients. A number of studies have demonstrated that this is treatment can be feasibly 
delivered with minimal adverse events [61].  
An alternate vaccination strategy is the use of synthetic tumour antigens for targeting the 
therapy. An example of this approach is the study by Sampson et al which utilised a peptide, 
PEP-3, which was derived from the mutated EGFRvIII found in 30-40% of GBM’s and 
conjugated to keyhole limpet hemocynain (PEP-3-KLH). In an animal tumour model mice 
vaccinated with PEP-3-KLH showed resistance to GBM [147]. Subsequent phase I trials 
demonstrated safety and development of an antigen specific immune response [148]. Phase II 
trials have shown a median OS of 26mths which was significantly improved over controls. 
Patient who showed EGFRvIII-specific antibody reactions had Median OS of 47.7mths vs. 
22.8 in other subjects [149]. A Phase III trial of PEP-3-KLH (rindopepimut; Celldex 
Therapeutics, Ma, USA.) is underway (Clinical Trials.gov identifier NCT01480479) [150]. 
 
Adoptive Cell Transfer 
Adoptive cell transfer (ACT) refers to cell therapies using NK cells, lymphokine-activated 
killer (LAK), tumour specific cytotoxic T-Cells (CTL) or tumour infiltrating lymphocytes 
(TIL) harvested from a tumour bearing host. These autologous tumour specific cells undergo 
ex vivo expansion and activation then are transferred back to the patient [7]. Harvesting of 
these cells can be from peripheral blood, tumour tissue or draining lymph nodes [8]. Up to 
75% of CD8+ cells undergo successful ex vivo expansion with a greater number of 
circulating T-cells at harvest achieving a better response [151, 152]. ACT has been applied to 
GBM employing various techniques with some promising early results[153, 154]. 
This technique provides a passive immunotherapy to give a tumour specific response. The 
benefits of this approach are the ability to give large numbers of cells that have a high 
specificity for tumour antigens. It also gives an opportunity for selection of effector cells that 
show the best anti-tumour activity away from the in vivo environment and effects of 
physiological or pathophysiological control [9]. The main effector cells for ACT are T-cells 
however other cell types may have a role such as NK cells. The cells suitable for ACT may 
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occur naturally such or if the desired characteristics are not available naturally they can be 
engineered, for example incorporating cytokines or co-stimulatory molecules [155-157].  
The disadvantages of ACT are difficulty in generation of sufficient numbers of cells for 
successful transfusion, ensuring adequate tumour antigen specificity, long term engraftment 
and maintaining effector function [158]. A significant problem with ACT is  transferring cells 
which retain the ability to self renewal and thus have persisting effector function.[159] To 
overcome this problem immunosuppressive cells and factors can be depleted through pre 
treatment conditioning with chemotherapy or whole body irradiation [160]. Myeloablative 
treatment with stem cell rescue has also been used with some success to allow proliferation of 
transferred T-Cells [161]. As always any myeloablative therapy has the potential to leave the 
patient prone to opportunistic infections.  
ACT can be further divided depending on the type of cell used for transfer into tumour. 
Rather than T-cells harvested from peripheral blood, TILs, and engineered T cells (ETC) can 
be used.  TIL therapy has been studied extensively in melanoma immunotherapy [7]. In this 
strategy the T-Cells are taken from fresh tumour. They then undergo selection and expansion 
using IL-2 and cell culture. This is limited by T-Cell yield from the tumour with only 30-40% 
of surgical specimens having sufficient cell numbers. Also 6 weeks is required for production 
of cells for infusion which is significant for aggressive tumours such as GBM. Despite these 
limitations it has proven to be the most effective of the ACT methods with objective response 
rates of greater than 50% in a number of melanoma studies [9].  
Some mouse models of ACT have shown a synergistic effect with vaccination [162, 163].  
As noted previously limitations for ACT include developing specificity for the T-Cells and 
prolonging the persistence of the transferred T-Cells. T-Cells engineered to express tumour 
antigen specific receptors would potentially overcome the poor antigen city of some tumours.  
Genetic modification of the T-Cells prior to transfer to enhance the life of these cells may 
reduce the need for potentially harmful myeloablative therapies prior to transfer.  
 
Immunotherapy as a synergist with Adjuvant Therapies 
Whilst there has been some encouraging results for immunotherapy in various cancer settings 
it has become more likely that immunotherapy will be of most clinical benefit in conjunction 
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with other treatments such as cytoreductive surgery, chemotherapy and radiotherapy [164, 
165].  
A corner stone of standard treatment for GBM is ionising radiation. The primary intention is 
for a direct cytotoxic effect on tumour cells. In addition to the direct effects it appears that the 
tumour micro-environment is also affected along with generation of inflammation [166]. T-
Cells are known to be sensitive to even low doses of radiation allowing for re-setting of the 
immune environment of tumours [164]. this sensitivity has been demonstrated in tumours 
resulting in clearance of the tumour field post radiotherapy allowing for repopulation with the 
transferred T-cells [167, 168]. In addition radiotherapy improved antigen presentation [169]. 
In mouse models MHC class I expression was enhanced by radiotherapy and improved 
response to immunotherapy [170].  
Chemotherapy and immunotherapy have been traditionally regarded as antagonistic  based on 
the assumption that chemotherapeutic agents result in immunosuppressant effects thus 
diluting any effect of therapy and that they generally act by inducing apoptosis in target cells 
which is non-inflammatory [171]. This assumption has been challenged by recent evidence 
that immunotherapy and chemotherapy can act in a synergistic fashion. This may be through 
elimination Tregs cells, activation of ACP’s, improved antigen presentation lymphopenia 
resulting in homeostatic T-Cell proliferation, disruption of the tumour microenvironment and 
increased susceptibility of tumour cells [165].  Wheeler et al compared patients who had 
received dendritic cell vaccination in conjunction with chemotherapy and those with 
chemotherapy or vaccination alone [172]. Combined therapy gave a 42% 2yr survival 
compared with 8% in single agent therapy; with significantly improve time to progression. 
Standard chemotherapy in GBM is Temozolomide. This has been shown to induce 
lymphopenia and decreased Tregs cells through blockade IL-2 receptors. Administration of 
anti-IL-2 anti-body whilst the patient was lymphodepleted reduced Tregs while allowing 
vaccine induced anti-tumour effector cell response [173].  
Given the possible interactions with existing proven therapies much care must be taken in 
when in the cycle of treatment immunotherapy should be introduced. Given the potential 
immune reset effects of radiotherapy and potentially synergistic effects with standard 
chemotherapy the most appealing time would be post radiation alternating with concurrent 
metronomic TMZ therapy. 
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Barriers to Immunotherapy and Antigen-Loss Variants 
The two major problems that hamper adoptive immunotherapy remain:  
1. The relative cost and technical difficultly in the ex-vivo expansion of suitable cells. 
2. The temporary tumour effect if the transferred cells fail to persist or engraft.  
These problems have lead to significant interest in vaccine therapies to circumvent these 
problems. In addition to these ex vivo problems the phenomena of antigen-loss variants may 
limit the effectiveness ACT. 
Tumour antigen specific immunotherapeutic approaches have the clear benefit of reducing 
the risk of autoimmune complications. In tumours antigen heterogeneity is the norm, thus 
individual tumour cells may express different phenotypes. Immunodominance refers to the 
preferential immunodetection of the dominant epitope of the many that are expressed by a 
target. The cells expressing the dominant epitope for which the therapy is targeted against 
will be cleared and cells expressing the previously recessive epitopes will survive allowing 
tumour regrowth [174].   
 
Vaccine studies have demonstrated the phenomena of antigen loss variants. As discussed 
earlier EGFRvIII has been targeted with a vaccine conjugated to keyhole limpet hemocyanin 
(PEP-3-KLH). In a mouse GBM model treatment failure with this vaccine was associated 
with loss of EGFRvIII expression in 80% of cases [147]. This was also seen in phase II 
human trials of the PEP-3-KLH vaccine indicating escape variants may be a mechanism of 
resistance [149, 175].  
Strategies such as whole tumour lysates or multiple antigen cocktails have be used in vaccine 
therapy to prevent the development of antigen loss variants. This carries an increased risk of 
autoimmune reaction.  A more elegant approach would be individual patient screening for 
suitable target antigens; this would however be difficult for widespread use in terms of 
resources and cost. Another alternative would be for identification of suitable target antigens 
on a population basis such as current practice with Flu vaccination.  
It is now clear that the heterogeneity inherent in GBM affects the response to 
immunotherapy. A study by Prins et al showed that in a dendritic cell vaccine trial those 
subjects with a mesenchymal subtype had increased CD3+ and CD8+ TIL’s and greater 
response to the experimental treatment [176]. The mesenchymal subtype is characterized by 
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over expression of pro-inflammatory genes and may represent a sub-type of tumour more 
suited to immunotherapy. 
 
1.9. HCMV Targeted Immunotherapy for GBM 
In a pilot study by a group at the University of California, a single GBM patient was 
administered dendritic-cells that had been pulsed with autologous GBM lysates as an adjunct 
therapy. A significant increase in the HCMV-specific T cell response was observed [110].  
This study highlighted the relative ease of eliciting an immune response against viral antigens 
which is in contrast to the difficulty of immunization against "self" tumour antigens.  
Anti-viral drug Valganciclovir which is used to treat HCMV infection has also been trialled 
in the setting of GBM. In a randomized, double-blind, placebo controlled trial with 42 
patients Stragiotto et al studied the use of Valganciclovir as an adjunct to conventional 
“Stupp protocol” treatment in a series of GBM patients [177]. They found no significant 
difference between groups with median overall survival of 17.9 vs. 17.4 months. Post hoc 
explorative analyses showed in these taking >6mths Valganciclovir survival was improved 
24.1mth vs. 13.1mths, with survival at 4 yrs 27.3% vs. 5.9%. These results suggest long term 
suppression of HCMV in GBM patients may reduce the aggressive characteristics of the 
tumour, thus improving survival. 
Our laboratory has been trialing the use of CMV specific adoptive T-cell therapy [178]. In a 
phase I trial in recurrent GBM patients had peripheral blood mononuclear cells (PBMC’s) 
were isolated from blood samples and stimulated in vitro with CMV peptides and IL-2 then 
infused as an adoptive T-cell therapy.  As one may expect recurrent GBM patients have poor 
life expectancy and of the 19 patients who were enrolled only 13 successfully had CMV 
specific T-cells expanded, 4 patients withdrew due to progressive disease prior to vensection 
and 2 had insufficient T-cells expanded due to poor precursor frequency.   Unfortunately 2 
patients died prior to infusion and one after only 2 infusions, leaving 11 patients who 
underwent the full course of T-Cell infusions.  In this group median survival was 403 days, 
ranging between 133 and 2,428 days. Importantly 4 of the subjects remained free of 
progressive disease within the study period. 
There is a number of developing therapeutic strategies targeting HCMV for GBM therapy 
there is no firm evidence of the utility of this approach and the field remains in its infancy.  
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1.10. Current Study 
CD8+ T-cells play a primary role in immune response to HCMV infection in 
immunocompetent individuals [179].  There is now significant evidence that HCMV is 
expressed in GBM.  Studies on a small number of GBM patients have demonstrated that 
although these patients had circulating HCMV-specific T-cells at detectable levels similar to 
healthy controls the majority of these cells were non-functional or displayed limited 
functionality [10].  
  The aim of this thesis is to examine the role of HCMV immune response in GBM patients. 
This will be done through clinical study and functional characterisation of Total and HCMV 
specific T-cell responses in GBM patients through gene expression analysis.  This will guide 
further pathway analysis to assess the mechanisms by which T-Cell function is inhibited in 
response to GBM.  The ultimate aim is to identify specific pathways impairing the host 
response to GBM and adapt therapeutic strategies to circumvent these.  
 
 
 
Key Points: 
• Despite intensive efforts GBM remains an aggressive incurable disease 
• The hosts immune response to GBM is ineffective due to a range of mechanisms 
• Evidence now suggests HCMV is present in GBM and modulates some of the 
malignant characteristics 
• Immunotherapy is a promising treatment strategy possibly utilising HCMV as a target  
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Chapter 2: Effects of CMV Serology status on Clinical Outcomes in GBM 
 
2.1.  Introduction 
First identified in 2002 by Cobbs as being present in GBM there is now considerable 
evidence that HCMV sequences and viral gene expression exist in most if not all malignant 
gliomas.  The evidence from current literature points to the virus acting not as an oncogenic 
virus but rather modulating the tumour and potentiating some of the malignant characteristics 
of GBM [6].   Studies showing an increased likelihood of antibodies against HCMV in GBM 
patients have been important in establishing the link between the virus and the tumour [103]. 
In addition studies have suggested that the strength of viral expression with in the tumour 
tissue is correlated with clinical outcome, however these studies have been contradictory to 
date [118, 119].  
This study therefore aims to examine the relationship between HCMV serology status and 
clinical end points of time to progression and overall survival. 
 
2.2. Methods 
Patients’ diagnosed with Glioblastoma Multiforme (GBM, WHO grade IV) were enrolled in 
an observational trial (QIMR ref p158, ethics approval from QIMR Berghofer Human 
Research Ethics Committee and Uniting Care Health Human Research Ethics Committee.) 
These patients had demographic information recorded and peripheral blood samples taken 
after informed consent.  
Histology was based on the pathology reports available from specimens received at surgery 
and slides were not reviewed. CMV serostatus was based on serum IgG >6IU  and IgM 
>0.8TV  regarded as seropostive.  
Clinical information regarding treatment was retrieved from retrospective review of patients’ 
notes. Performance score was graded by the Karnofsky scale based on review of initial 
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clinical consultation.  Initial treatment was assessed as whether they underwent the “gold 
standard” therapy of gross total resection (GTR), radiating therapy (Rx) and con-current 
Temozolomide (TMZ). Insertion of GLIADEL
®
 Wafer (polifeprosan 20 with carmustine 
implant; Eisai Inc, Woodcliff Lake, New Jersey, USA) was recorded in operation notes. 
Metronomic TMZ was defined as cyclic dosing of monthly 5 day cycles of treatment in an 
ongoing manner. At recurrence the treatment was defined as surgery, second line 
chemotherapy i.e. not TMZ, and inclusion in the adoptive T-cell therapy phase 1 trial being 
conducted in the same institution.  
Date of death was recorded for patients from clinical notes. If the patient was alive the last 
date of follow up was recorded. Progression was based on evidence of progression of disease 
on imaging criteria in conjunction with clinical notes, in most cases magnetic resonance 
imaging (MRI) was the standard modality. The date of progression was recorded as the date 
of the scan showing progression. In cases where pseudo-progression was queried PET scans 
were often performed for confirmation.  
11 of the patients who were HCMV seropostive went on to be enrolled in T-Cell adoptive 
therapy phase I trial after recurrence, however not all of these patients then received T-cell 
therapy[178].  Therefore further analysis was performed excluding these patients to avoid any 
bias that may have been introduced. 
 
Statistical Methods 
The summary statistics of patients were HCMV seropostive and HCMV seronegative were 
presented respectively by number (percentage) or median (IQR) as appropriate.  
All caused mortality and progression free survival for the both groups were compared using 
Kaplan-Meier curves and the log-rank test, and the corresponding median survival time was 
obtained. For the analyses, time to death or censoring was defined as the time between the 
last follow-up date and the date of diagnosis. Time to progression or censoring was defined 
as the time between the date of the first recurrence or the last follow-up date and the date of 
diagnosis.  
Furthermore, using multivariate Cox regression models, all caused mortality and progression 
free survival for the both groups were compared after adjusting for age and KPS. The 
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aforementioned analyses were also repeated for the subset of patients who did not participate 
in the T-cell Adoptive Therapy phase I trial. 
2.3. Results 
 
80 patients were enrolled in the study. There were 6 patients for whom no follow up data was 
available so were excluded from analysis. A further 8 patients had follow up available until 
recurrence but were lost to follow up prior to death; these patients were included in analysis 
for progression free survival. The overall cohort characteristics are summarized in table 2.1.  
 
Table 2.1: Descriptive statistics on the study cohorts 
 HCMV - HCMV+ 
N* 29 (39.2) 45 (60.8) 
Male* 19 (65.5) 28 (62.2) 
Ageγ 52 (42, 60) 54 (49, 62) 
KPSγ 90 (80, 90) 85 (80, 90) 
Histology   
Primary GBM* 22 (75.9) 35 (79.5) 
Secondary GBM* 3 (10.3) 3 (6.8) 
AA (WHO III) * 3 (10.3) 6 (13.6) 
Brainstem Glioma* 1 (3.4) 0 (0) 
Initial Treatment   
GTR/Rx/TMZ* 25 (86.2) 42 (95.5) 
Gliadel* 13 (44.8) 22 (50) 
Metronomic TMZ* 29 (100) 40 (93) 
Treatment for Recurrence   
Surgery* 18 (75) 28 (68.3) 
2nd Line Chemotherapy* 14 (60.9) 31 (75.6) 
T-cell Trial* 0 (0) 11 (26.8) 
*Number (%); γMedian (IQR) 
 
In the cohort of 29 patients with HCMV– serology status, 66 % were male, median (IQR) age 
was 52 (42, 60) years, and median (IQR) KPS was 90 (80, 90). 76 % had primary GBM, 10 
% had secondary GBM and AA respectively and 1 % had Brainstem Glioma. 86 % received 
GTR/RX/TMZ as initial therapy, 45 % received Gliadel and 100 % received Metronomic 
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TMZ. When the condition recurred, 75 % received further surgery, 61 % received second line 
chemotherapy and 0 % received T-cell treatment. 
In the cohort of 45 patients with HCMV+ serology status, 62 % were male, median (IQR) age 
was 54 (49, 62) years, and median (IQR) KPS was 85 (80, 90). 80 % had primary GBM, 7 % 
and 14 % had secondary GBM and AA respectively. 96 % received GTR/RX/TMZ as initial 
therapy, 50 % received Gliadel and 93 % received Metronomic TMZ. When the condition 
recurred, 69 % received further surgery, 76 % received second line chemotherapy and 27 % 
received T-cell treatment. 
The median overall survival of patients with GBM who were HCMV -ve was 719 days 
compared to 780 days for those who were HCMV+; this difference was not statistically 
significant. When patients who were enrolled in the therapeutic trial were excluded, the 
median overall survival was 613 days for HCMV+ patients and 673 days for HCMV–. Log 
rank tests comparing these groups with and without the trial patients (fig 2.1) demonstrated 
that there was no significant difference in overall survival (p=0.553 all subjects and p=0.462 
with trial patients excluded).  
Median progression free survival was 344 days for HCMV +ve patients and 348 days for 
HCMV–patients. With trial patients excluded, median progression free survival was 327 days 
for HCMV+ patients and 299 days for HCM- patients. Log rank tests comparing these groups 
with and without the trial patients (fig 2.2) demonstrated that there was no significant 
difference in overall survival (p=0.453 all subjects and p=0.989 with trial patients excluded). 
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 a) 
 
b) 
 
Fig 2.1: All cause mortality. Kaplan-Meier curves for all caused mortality for patients with 
HCMV+ and HCM- serology; a) all patients. b) Patients who did not participate in the T-cell 
Adoptive Therapy phase I trial. 
a) 
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b) 
  
Fig 2.2: Progression free survival. Kaplan-Meier curves for progression free survival for 
patients with HCMV+ and HCM-  serology; a) all patients. b) Patients who did not 
participate in the T-cell Adoptive Therapy phase I trial. 
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After adjusting for age and KPS, HCMV+ serology patients seemed to have higher mortality 
(HR 1.34, 95% CI 0.59 – 3.07) and recurrence risks (HR 1.43, 95% CI 0.56 – 2.07) compared 
to patients with HCMV- serology, though statistically not significant (Table 2.2). The results 
for patients excluding those who participated in the T-cell Adoptive Therapy phase I trial 
were also similar. 
 
Table 2.2: Hazard Ratios for Mortality and Progression Free Survival. Association of 
HCMV+ serology status with all caused mortality and progression free survival compared to 
HCMV- serology status, adjusted for age and KPS: Cox regression analyses, for all patients 
and for patients who did not participate in the T-cell Adoptive Therapy phase I trial. 
 HR (95 % CI) p-value 
Mortality   
CMV+ 1.34 (0.59, 3.07) 0.486 
CMV+ (No Trial Pts) 1.65 (0.69, 3.93) 0.263 
Progression Free Survival   
CMV+ 1.43 (0.78, 2.63) 0.251 
CMV+ (No Trial Pts) 1.08 (0.56, 2.07) 0.823 
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2.4. Discussion 
This study shows no significant difference in rate of progression and overall survival in GBM 
patients between those that have positive HCMV serology and those who are negative.  
The existence of HCMV in GBM has been controversial but the evidence has now been 
replicated in a number of studies with the weight of evidence now pointing to HCMV being 
present in GBM tissue and acting as an oncomodulatory virus, potentiating the malignant 
characteristics [6]. This has been supported by studies showing that the strength of viral 
expression in the tumour is correlated with clinical outcome [118]. Despite the presence of 
CMV within tumour tissue, epidemiological studies have failed to show a clear link between 
CMV sero-status and glioma risk. The relationship between the existence of CMV in glioma 
and clinical aspects of the disease remains unclear [180]. In terms of clinical outcome a 
recently published study addressed the impact of anti-HCMV antibodies (IgG and IgM) on 
GBM outcome. Using cohorts from the Harris County Case-Control Study they found an 
increasing risk of glioma with low levels of anti-HCMV IgG however there was no 
association with survival and antibody level [181].  The current data supports this study in 
showing that CMV serostatus has no effect on clinical outcome. 
Prior exposure to HCMV in the host could the theory result in improved anti-tumour 
response against HCMV antigen expressing GBM tissue from a pre-primed immune system. 
However, as discussed in the introductory chapter HCMV may also contribute to immune 
escape of the tumour though the complex immunoescape mechanisms that allow it to persist 
for life. In addition  it is already known that HCMV specific T-cells in GBM patients are less 
functional which would correlate with the lack of clinical benefit of pre-exposure to HCMV 
[10].  Recent studies questioning the effects of expression of HCMV in clinical outcome 
would suggest that not only does the presence of HCMV have limited effect on the tumour 
characteristics but that it does not alter the immune-reactivity of the tumour [119]. This 
would correlate with the lack of difference between the two groups in this study. 
There are a number of criticisms with this study that mean interpretation must been cautious. 
Firstly it is a retrospective study with the inherent bias data collection in this manner. An 
example of such bias may be seen in the recurrence data. As these patients were not enrolled 
in a therapeutic trial the follow up was performed on an ad hoc non-standardised basis 
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meaning the time to progression could be inaccurate. However survival data is a robust 
endpoint which is not as affected by the retrospective nature of the data collection. 
Unfortunately a relatively large number of patients had incomplete follow up data potentially 
negating this benefit. The problem of incomplete data also exacerbates the relatively small 
sample size of 80 patients for a study of this type. Also tumour related confounding factors 
such as molecular sub-type and MGMT methylation status are not accounted for in this 
analysis. Other factors that may impair the correlation to clinical outcomes include lack of, 
and limited information on some confounding variables such as functional and 
socioeconomic status. 
 
 
Key Points: 
• There is no difference in survival or time to tumour progression between patients with 
GBM who have positive HCMV serology and those who do not. 
• This suggests prior exposure to HCMV does not affect clinical outcomes in GBM. 
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Chapter 3: Gene Expression analysis of CMV Specific and Total CD8+ T-cells in 
patients with GBM. 
 
3.1. Introduction 
This study aims to isolate CD8+ T-cells and CMV specific CD8+ T-cells from GBM patents 
using  Fluorescence Activated Cell Sorting (FACS)  to then allow custom gene microarray 
analysis of expression  of  92 genes that have been  described to be important for regulation 
of CD8+ T-cells during HCMV infection [182]. These genes are relevant for several 
functional categories: cell division and metabolism, survival and apoptosis, effector 
molecules, migration and adhesion, transcription factors, chemokines and cytokines, cytokine 
receptors, differentiation and exhaustion [182]. These studies will help to functionally 
characterise HCMV-specific T-cell responses in GBM patients and help guide further 
pathway analysis to assess the mechanisms by which T-Cell function is inhibited in response 
to GBM.   
 
3.2. Methods 
 
Patient Selection 
Patients’ diagnosed with high grade gliomas, either Anaplastic Astrocytoma (WHO III) or 
Glioblastoma Multiforme (WHO grade IV), were enrolled in an observational trial (QIMR ref 
p158, ethics approval from QIMR Berghofer Human Research Ethics Committee and Uniting 
Care Health Human Research Ethics Committee). These patients had blood samples taken 
after informed consent and PBMC’s isolated by Ficoll Paque (Amersham Pharmaica Biotech, 
Uppsala, Sweden) density centrifugation. These PBMC’s were then cyropreserved.  Subjects 
were selected at random from samples of both CMV negative and positive groups. Age, Sex 
and CMV serology matched healthy control donors were selected from the laboratory sample 
bank. 
Flow Cytometry 
PBMCs were revived from cyropreserved stocks and left to recover for 1h at 37 °C in growth 
medium (10ml RPMI 10% Foetal Calf Serum). Samples were stained with APC labelled 
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pMHC multimers if CMV seropositive, followed by staining for surface markers with 
antibodies CD3-PE-Cy, CD14-pacific blue, CD19-AlexaFluor450, CD8-PerCpCy5.5 and 
CD4-FITC to allow for separation of monocytes, B cells and T cells. After filtering the cell 
suspension through a nylon mesh for removal of cell clumps, total CD8+ T cell and HCMV 
specific CD8+ T cell populations were isolated using a BD FACSAria™ Cell Sorting 
System (Becton, Dickinson and Company, Franklin Lakes, New Jersey, USA). 
Gene expression analysis 
The CD8+ and CMV specific CD8+ cells underwent RNA isolation using RNeasy Micro Kit 
(Qiagen) according to manufacturer’s instructions. RNA equivalent to 3000 cells was then 
transcribed to cDNA using AB high capacity RNA-to-cDNA kit. The cDNA then underwent 
pre-amplification with Taqman PreAmp Master Mix kit prior to gene array analysis 
performed with Taqman Gene expression assay and a TaqMan Array Micro Fluidic Cards 
(see appendix 1 for list of genes, all reagents from Life Technologies) using ABI Viia 7 real 
time PCR by the comparative CT method. Data was imported into GeneSpring v12.5, and 
normalised to housekeeping genes 18s, actin and b2m.  Data was filtered to remove any 
target that was not expressed at a Ct value of less than 35.  Groups were then compared using 
an unpaired t-test with or without multiple testing correction (MTC) using the Benjamini-
Hochberg method.  Results where p<0.05 were considered significant.  Genes where there 
were significant differences in expression between sample populations and controls were 
entered into IPA (Ingenuity® Systems, www.ingenuity.com) software for pathway analysis. 
Clinical Data 
Clinical data was gathered from review of the patient files. Clinical outcomes were measured 
by time to progression defined by progression on follow up imaging and overall survival 
based on date of death.  Sub-groups for analysis were time to progression < 1yr and > 1 yrs, 
Overall survival >18mths and < 18mths. 
 
   53 
 
3.3. Results 
20 subjects were selected for analysis with 10 of these having CMV negative serology and 10 
CMV positive. The sample population clinical data is shown in table 3.1.  
 
Table 3.1: Characteristics of Subjects for Gene Expression Analysis 
   Subjects CMV+ Subjects CMV- Total 
Number  10 10 20 
 Age (median)   49 yrs 58 yrs 55 yrs (range 21-74) 
Gender         
Male  3 5 8 
Female  7 5 12 
Histology         
Primary GBM  
7 8 14 
Secondary GBM  2 1 4 
Anaplastic 
Astrocytoma  
1 1 2 
Time to recurrence 
(median)  
    352.5 days  
(range 84- 4651) 
      
Overall Survival 
(median)  
     649 days  
(range 236- 4851)  
 
In all subjects sufficient total CD8+ cells were isolated to allow for RNA extraction, however 
the PCR reactions failed in 2 samples leaving 8 CMV +ve subjects and 10 CMV-ve subjects 
for analysis.  
 
Inadequate numbers of CMV specific CD8+ cells were isolated from the PBMC samples 
following staining and FACS sorting to enable gene expression analysis in 4 CMV +ve 
subjects leaving 6 samples of CMV specific CD8+ cells in which gene expression failed in 1 
leaving 5 subjects for CMV specific analysis. After analysis statistically significant results 
were reviewed.  
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Analysis of CMV specific T-cells in GBM patients compared with controls showed 
statistically significant down regulation of a number of genes (table 3.2). These genes 
represented two distinct subgroups related to effector function (GZMA, GZMB and SPON2) 
and the exhausted phenotype of T-cells usually seen in persistent virus infection (KLRD1, 
ZNF683, CD244, and PTGER2) [182]. There was also up regulation of the PDCD1 gene 
which codes for PD-1 a co-inhibitory molecule. Analysis of the total CD8+ T-cell population 
in GBM patients compared with controls showed a pattern of down regulation of effector 
promoting genes and up regulation of inhibitory genes shown in table 3.2. The genes that 
were up regulated included: BTLA a co-inhibitory molecule; TYMS and CDCA7 which code 
for proteins critical in DNA replication; cytokine genes IL7R, CCL4L1 and CX3CR1; 
GZMB which codes for a serine protease and NR3C2 a nuclear mineralocorticoid receptor 
with unknown function in immune cells.  There was down regulation of TNFS14 (LIGHT) a 
co-stimulatory molecule and GZMK a granzyme protease. 
The sub-group analysis based on clinical outcomes of time to progression and overall 
survival is shown in table 3.3 and fig.3.3 and fig 3.4.  In patients with longer progression free 
survival there was down regulation of the pro-apoptotic BAD gene, chemokines receptor 
CXCR5 and cell cycle enzyme TYMS. Improved overall survival was associated with down 
regulation of BTLA and NR3C2.  
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Fig 3.1: Changes in gene expression in CMV Specific T-Cells of GBM. Heat map and graph showing the genes for whom statistically 
significant Fold Change (shown with standard deviation) was observed in CMV specific T-Cells between GBM patients and age, sex and HLA 
type matched healthy controls 
GBM Control 
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Fig 3.2: Changes in gene expression in the total population of CD8+ T-Cells of GBM 
patients. This table shows the gene for whom statistically significant Fold Change (shown 
with standard deviation) was observed in the total population of CD8+ T-Cells between 
GBM patients and age, sex and HLA type matched healthy controls.Table 3.2: Changes in 
Gene Expression for CMV Specific T Cells in GBM patients.
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Table 3.2: Changes in Gene Expression for CMV Specific T Cells in GBM patients. 
Gene 
Code 
Name 
Regulatio
n 
Fold 
Chang
e 
P= 
 
Description Also known as 
PDCD1 Programmed cell death 
protein 1 
up 4.223 0.002  Immune regulation CD279; PD-1; PD1; SLEB2; hPD-1; 
hPD-l 
CD244 n/a down -3.483 0.001  Natural Killer Cell Receptor 2B4; NAIL; NKR2B4; Nmrk; 
SLAMF4 
GZMA Granzyme A down -3.859 0.026  T-Cell and NK cell serine protease CTLA3; HFSP 
GZMB  Granzyme B down -3.95 0.036  T-Cell and NK cell serine protease CCPI; CGL1; CSP-B; CSPB; CTLA1; 
CTSGL1; HLP; SECT 
ZNF68
3 
Zinc Finger Protein 683 down -4.836 0.017  May be involved in transcriptional regulation Hypothetical Protein MGC33414 
PTGER
2 
Prostaglandin E2 receptor down -4.972 0.003  Prostaglandin receptor for prostaglandin E2 EP2 
KLRD
1 
Killer cell lectin-like receptor 
subfamily D 1 
down -6.02 0.002  Killer cell lectin-like receptor CD94 
SPON2 Spondin 2 down -12.936 0.007  Cell adhesion protein, a chemoattactant for 
monocytes and macrophages 
DIL-1, M-Spondin, Mindin 
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Table 3.3: Changes in Gene Expression for total CD8+ T-cells in GBM patients. 
Gene 
Code 
Name Regulation 
Fold 
Change 
P= Description Also known as 
ZNF683 Zinc Finger Protein 683 up 3.84 0.02 May be involved in transcriptional regulation Hypothetical Protein 
MGC33414 
TYMS Thymidylate synthase up 3.71 0.017 A critical enzyme in DNA replication HST422; TMS; TS 
CDCA7 Cell division cycle-associated protein 
7 
up 3.33 0.001 Induces growth and clonogenicity in 
lymphoblastoid cells 
JPO1 
NR3C2 nuclear receptor subfamily 3, group C, 
member 2 
up 3.19 0.023 mineralocorticoid receptor MCR; MLR; MR; NR3C2VIT 
CCL4L1 C-C motif chemokine 4-like up 3.17 0.019 Codes for CC motif chemokines 4- like AT744.2; CCL4L; LAG-1; 
LAG1; SCYA4L 
CX3CR1 CX3C chemokine receptor 1 up 3.00 0.029 Cytokine receptor CCRL1; CMKBRL1; 
CMKDR1; GPR13; GPRV28; 
V28 
BTLA B- and T-lymphocyte attenuator up 2.82 0.013 T-Cell inhibition via interaction with tumor 
necrosis family receptors 
BTLA1; CD272 
GZMB Granzyme B up 2.59 0.028 T-Cell and NK cell serine protease CCPI; CGL1; CSP-B; CSPB; 
CTLA1; CTSGL1; HLP; SECT 
CD244 n/a up 2.37 0.031 Natural Killer Cell Receptor 2B4; NAIL; NKR2B4; Nmrk; 
SLAMF4 
IL7R interleukin-7 receptor up 1.89 0.017 Cytokine receptor CD127 
GZMK Granzyme K down -1.86 0.034 T-Cell and NK cell serine protease TRYP2 
TNFSF14 Tumor necrosis factor ligand 
superfamily member 14 
down -2.18 0.015 A costimulatory ligand for HVEM CD258; HVEML; LIGHT; 
LTg; TR2 
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Fig 3.3: Changes in gene expression in the total population of CD8+ T-Cells in Long   
surviving GBM patients. Bar graph showing the fold change (with SD) for genes with 
statistically significant differences in  expression in the total population of CD8+ T-Cells 
of GBM patients who survived > 18mths compared with those who survived <18ths.  
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Fig 3.4: Changes in gene expression in Total CD8+ T-Cells of GBM patients based on 
progession free survival. Bar graph showing the fold change (with standard deviation) for 
genes with statisicatlly significant differences in  expression in the Total population of CD8+ 
T-Cells of GBM patients who had progession free survival  > 12mths compared with those 
who had progression free survival  <12mths. Table 3.4: Changes in Gene Expression for 
total CD8+ T-cells in GBM patients based on clinical outcomes (time to progression and 
overall survival.
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Table 3.4: Changes in Gene Expression for total CD8+ T-cells in GBM patients based on clinical outcomes (time to progression and overall 
survival) 
Gene 
Code 
Name 
Regulatio
n 
Fold 
Change 
P= Description Also known as 
Total CD8+ T-cell population in GBM patients; Time to Progression >12mths vs. <12mths. 
BAD Bcl-2-associated death promoter down -3.113 0.037 
Pro-apoptotic member of the Bcl-2 gene family 
involved in initiating apoptosis. 
BBC2; BCL2L8 
CXCR5 Chemokine receptor CXCR3 down -4.502 0.037 
G protein-coupled receptor in the CXC chemokine 
receptor family 
BLR1; CD185; MDR15 
TYMS Thymidylate synthase down -6.380 0.01 A critical enzyme in DNA replication HST422; TMS; TS 
CD8+ T-cell population in GBM patients; overall survival >18mths vs. <18mths. 
NR3C2 
nuclear receptor subfamily 3, group 
C, member 2 
up 5.147 0.033 mineralocorticoid receptor 
MCR; MLR; MR; 
NR3C2VIT 
       
BTLA B- and T-lymphocyte attenuator down -3.709 0.026 
T-Cell inhibition via interaction with tumour necrosis 
family receptors 
BTLA1; CD272 
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Pathway analysis of the changes in gene expression outlined above resulted in significant 
association for the CMV specific group with the Cell Death and Survival, Cell-To-Cell 
signalling and Interaction networks. The total T-Cell population analysis showed significant 
association with the Cellular development, Cellular Growth and Proliferation, 
Haematological System Development and Function network (Fig. 3.5 and 3.6).  
 
Fig 3.5: Key for Pathway Analysis Diagrams. (IPA; Ingenuity® Systems, www.ingenuity.com)
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Fig 3.6:  Pathway Analysis of Gene Expression Data from the CMV Specific T-Cell 
population in GBM patients. Coloured genes are those identified by the gene expression 
analysis in the current study.  The solid lines represent direct interactions between genes, 
dotted lines represent and indirect interaction. 
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Fig 3.7:  Pathway Analysis of Gene Expression Data from the total T-Cell population in 
GBM patients. Coloured genes are those identified by the gene expression analysis in the 
current study.  The solid lines represent direct interactions between genes, dotted lines 
represent and indirect interaction.  
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3.4. Discussion 
This analysis of CMV specific CD8+T-Cells in GBM patients showed down regulation of 
genes that are important for effector function and also a number of markers of the exhausted 
phenotype of T-cells usually seen in persistent virus infection [183].  These genes were 
GZMA, GZMB, SPON2, KLRD1, ZNF683, CD244, and PTGER2.  Down regulation of 
these genes could lead to the impaired functionality that has been demonstrated in this sub-
population of CD8+ cells in GBM patients. 
KLRD1, CD244 and PTGER2 are markers of the exhausted T-Cell phenotype seen in 
persistent virus infection.  This is a subset of cells characterised by poor function with 
reduced proliferation, cytotoxicity and cytokine secretion in response to stimulation [71]. 
This finding would contradict the suggestion that many of the CMV specific CD8+ cells are 
of this exhausted phenotype. This may indicate inhibitory mechanisms other than the 
exhaustion pathway may be of more importance in GBM mediated inhibition of T-cell 
function. Supporting this idea is that ZNF683, a homologue of PRDM1 which codes for 
Blimp-1 a transcription factor critical for establishment of the exhausted phenotype, was seen 
to be down regulated [182].  There was up regulation of PDCD1 which codes for immune 
modulating co-inhibitory molecule PD-1. Other key immune modulating molecules such as, 
Tim-3 and LAG3 genes were unchanged.  
In contrast to the pattern seen in the CMV specific cells the total CD8+ population showed  
up regulation of many genes associated with T-cell exhaustion such as CD244, ZNF683 
suggesting that this pathway may be of importance [71].  Other up regulated genes included 
cytokine receptor IL7R and chemokine receptor CX3CR1 and CCL4L1; genes important for 
the cell cycle and division CDCA7 and TYMS; the mineralocorticiod receptor NR3C2 which 
has unknown function [182].  
 In addition to the genes already mentioned analysis of the total CD8+ T- Cell population in 
GBM patients revealed up regulation of BTLA and down regulation of the gene coding for 
LIGHT. These co-molecules when expressed in the surface membrane of the cell interact 
with the same receptor herpes virus entry mediator (HVEM). BTLA forms an inhibitory 
complex on interaction with HVEM and is usually down regulated as naive T-Cells 
differentiate to effector cells. The LIGHT protein binds to HVEM to give a co-stimulatory 
signal to T-Cells promoting proliferation and effector function [184]. The pattern of up 
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regulation of the inhibitory BTLA and the down regulation of LIGHT is therefore consistent 
with overall inhibition of T-Cell function.  
In patients with longer progression free survival there was down regulation of pro-apoptotic 
BAD gene, chemokine receptor CXCR5 and cell cycle enzyme TYMS. Interestingly there 
was an association with improved overall survival with down regulation of BTLA which 
supports a possible role in tumour mediated immune suppression as discussed earlier. There 
was also down regulation of NR3C2, the role of which is unclear in immune regulation. 
All of the changes in gene expression identified by this data may be of importance and 
require further pathway analysis to delineate their importance. 
Network analysis of the gene expression data showed a common convergence in both the 
CMV specific and total T-cell population on the IL12 complex. This cytokine has been of 
interest as it is a promoter of the TH1 immune response [95]. IL12 has been used in oncolytic 
virus therapy in GBM and other cancers. These viruses replicate within tumour but not 
normal tissue and act to attack the tumour via their inherent cytolytic activity and by 
generating an immune response [95]. Indirect interaction with IL12 shown in this pathways 
analysis may suggest that this cytokine could be important in GBM T-cell interaction. 
In summary this study identifies a number of candidate genes involved in T-Cell inhibition in 
GBM. One potential pathway for further investigation from this study is the HVEM pathway 
and its ligands BTLA and LIGHT.  
Key Points: 
 
• In GBM patents CMV Specific CD8+ T-cells show a pattern of down regulation of 
genes promoting effector function 
• In GBM patients the Total CD8+ T-cell population displays a pattern of up regulation 
of inhibitory genes and down regulation of promoter genes 
• The HVEM/BLTA/LIGHT pathway may be an important inhibitory pathway and 
warrants further investigation 
• Network analysis highlights the potential importance of IL12 in GBM immune 
avoidance. 
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Chapter 4: The HVEM, BTLA and LIGHT network in GBM patients 
 
4.1. Introduction  
The results of gene expression analysis of CD8+ T-cells in the previous chapter revealed that 
in GBM patients the total CD8+ population showed up regulation of the inhibitory co-
stimulatory molecule BTLA and down regulation of the co-stimulatory molecule LIGHT. 
These molecules are both ligands for the HVEM receptor. This pathway is therefore a good 
candidate for further investigation.  
The aim of this set of experiments is to confirm the findings of the gene expression analysis 
and confirm that the changes seen in BTLA/LIGHT/HVEM expression are seen in the 
expression of the proteins they code for on the cell surface using FACS analysis. 
 This network consists of the Herpes Virus Entry Mediator (HVEM) receptor and its ligands 
LIGHT ( Lymphohotoxin-like, exhibits Inducible expression and competes with herpes 
simplex virus Glycoprotein D for HVEM, a receptor expressed by T-
lymphocytes/TNFSF14/CD258) and BTLA (B and T Lymphocyte Attenuator/CD272).  
HVEM was first identified as a route of cell entry for HSV; it is now known to be an 
important regulator of the immune response signalling through JNK1, NF-κB and AP-1 in 
response to infection [185].  It is expressed in blood vessels, brain, heart, kidney, liver, lung, 
prostate, spleen and thymus, along with resting T-cells and naive memory B-cells [94]. It has 
the unique property of being able to interact with the members of the two superfamilies of co-
signalling molecules the TNFR family and Ig family in LIGHT and BLTA, respectively.  The 
extracellular compound of HVEM has three cysteine rich domains at the C-terminus, the 
characteristic of the TNF superfamily. On the N terminus of HVEM has an area known as the 
DARC (DARC for gD and BTLA binding site on the TNFR HVEM in CRD1) side which is 
the site of BTLA binding [186]. HVEM is strongly expressed in T-cells in their resting state 
and down regulated on activation [187].   
BTLA is a 70KDa type I membrane glycoprotein of the CD28 family. BTLA binding with 
HVEM results in SHP1/SHP2 phosphatase activity inhibiting T-cell activation.  Normal 
expression is seen on B cells, T-Cells and dendritic cells. During normal differentiation of 
naive T-cells to effector cells BTLA expression is down regulated. 
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LIGHT is a type 2 transmembrane protein commonly expressed in spleen, brain, kidney and 
activated CD8+ T-Cells. Normal expression of this receptor is on T-cells, B-Cells, NK cell, 
monocytes and immature DC’s.  
The binding of LIGHT to HVEM results in T-cell stimulation, B-cell co-stimulation, plasma 
cell differentiation, Ig secretion and the maturation of DC’s. In addition LIGHT is believed to 
down-regulate its own ligand, HVEM, as a self regulatory mechanism [188]. Interaction of 
HVEM and LIGHT must be between adjacent cells (trans) due to the crystalline structure. On 
the other hand BTLA can be co-expressed on the same cell resulting in interaction (cis).  
Interaction of BTLA with HVEM in a cis or trans configuration forms a HVEM/BTLA 
complex blocking interaction with LIGHT and overall an inhibitory signal is generated. Thus 
HVEM has bidirectional signalling. This mechanism is believed to act in a cis- configuration 
to regulate T-cell function by blocking immune “noise”. Within tumours HVEM expressed in 
the tumour tissue is believed to act in a trans- configuration to modulate the immune 
response [185].   
  
 
Figure 4.1: The HVEM/BTLA/LIGHT pathway. HVEM and BTLA affect cell function 
both through Trans interactions between cells and Cis configurations between molecules on 
the same cell. ( modified from: Paulos et al. Putting the brakes on BTLA in T cell–mediated 
cancer immunotherapy. J Clin Invest. 120(1): 76–80, 2010) 
 
Interestingly a number of malignancies have shown elevated expression of HVEM [189]. 
This includes chronic lymphocytic leukaemia (CLL), lymphoma, a number of solid tumours 
as well as  metastases and melanoma [187]. In melanoma tumour specific T-cells have been 
shown to have persistent BLTA expression and reduced production of IFN-γ [190]. Up-
regulation of BTLA and PD-1 has been shown to be important in inhibition of T-cell 
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expansion. Blocking of BTLA along with other inhibitory receptors has been shown to 
potential reverse the hypo-responsiveness of T-cells in melanoma patients (Fig 1.7) [184]. In 
tumour models forced expression of LIGHT has resulted in T-cell activation and anti-tumour 
effect [191].   
 
 
Figure 4.2: The HVEM Network in Tumour Models. HVEM/BTLA/LIGHT interaction in 
a trans configuration with tumour specific T-cells in melanoma models resulting in an overall 
inhibitory signal that is theoretically released by blockage of BTLA (modified from:  Pasero 
et al. The HVEM network: new directions in targeting novel co-stimulatory/co-inhibitory 
molecules for cancer therapy. Current Opinion in Pharmacology. 12(4: 478-85, 2012.) 
4.2. Methods 
Peripheral blood samples were taken from patients enrolled in an observational trial (QIMR 
ref p1558, ethics approval from Bancroft Centre human Research Ethics Committee and the 
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uniting Health Human Research Ethics Committee). PBMC’s were isolated and 
cyropreserved as previously described.  Twenty Subjects were selected with ten subjects 
being HCMV seropostive and ten HCVM seropositive. Age, Sex and CMV serology matched 
healthy control donors were selected from the laboratory sample bank.  From the 
observational trial cohort 15 subjects had tissue samples available for immunohistochemistry 
analysis. 
Flow Cytometry 
PBMCs were revived from cyropreserved stocks and left to recover for 1h at 37 °C in growth 
medium (RPMI 10% FCS). Samples were stained with APC labelled HCMV dextramers 
followed by staining for surface markers with antibodies CD8-AF700 and CD4-FITC to 
allow for separation of CD8+ T-cells. The cells where then stained with anti-BTLA-PerCP, 
anti-HVEM, and anti-LIGHT-biotin.  Secondary staining was performed with BV421-
Streptavidin and the cells were preserved in PBS-2% Paraformaldehyde.  Analysis was then 
performed using LSR 4 laser Fortessa Flow Cytometer (Becton, Dickinson and Company, 
Franklin Lakes, New Jersey, USA with FACS Diva software (BD Biosciences). Post-
acquisition analysis was conducted using FlowJo software (TreeStar). In each group the % of 
total CD8+ staining positive for each molecule was calculated along with mean florescence 
intensity (MFI).  Comparison was made between GBM patients and the control group along 
with total CD8+ and CMV specific CD8+ groups using unpaired t-test on GraphPad Prism 
version 6.00 for Windows, (GraphPad Software, La Jolla California USA, 
www.graphpad.com.) with p < 0.05 considered significant. 
Immunohistochemistry 
Surgical samples were fixed in 4% neutral buffered formalin overnight then transferred to 
70% ethanol before processing. Paraffin wax processing consisted of incubating the samples 
in a series of ascending grade alcohols from 70% to 100%, clearing in xylene and infiltrating 
with molten paraffin wax at 60oC over a period of several hours. 4µm paraffin sections were 
cut from embedded samples and floated onto a 37oC waterbath and collected onto Menzel 
Superfrost Plus slides and stored at 4
◦
C prior to immunohistochemical staining.  
Immunohistochemical staining for HVEM was carried out using mouse monoclonal anti-
body to HVEM (MM0332-5S1, ab89479, Abcam, Cambridge, UK).  Sections were dewaxed 
and rehydrated through descending alcohol to water series using standard protocols. 
Specimens were then subject to 20 minutes heat antigen retrieval at 121
o
C in a pressure 
cooker.  Endogenous alkaline phosphatase was blocked by incubating slides in Levamisole 
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and nonspecific antibody binding was inhibited by incubating the sections in Background 
Sniper blocking reagent. The sections were then incubated overnight at 4
o
C with the primary 
antibody diluted 1:70 in Da Vinci Green antibody diluents. After washing MACH2 Mouse -
alkaline phosphatase secondary antibody was applied for 45 minutes. Signals were developed 
in Warp Red chromogen for 10-15 minutes (all reagents Biocare Medical).  Finally sections 
were lightly counterstained in Haematoxylin and dehydrated through ascending graded 
alcohols.  
Two independent Pathologists analysed each slide at high power. Expression of HVEM was 
graded according to intracellular location (cytoplasm, membrane or intra nuclear) along with 
intensity (grade 0 = no signal, 1 = weak, 2 = moderate, 3 = high). 
 
4.3. Results 
 
The % of total cells positive for each molecule along with the mean fluorescent intensity 
(MFI) was calculated for each sample. A representative example of the gating strategy is 
shown in Fig 4.1. 
In the total CD8+ analysis mean BTLA expression in GBM vs. controls was 2.16% (SEM +/- 
0.3187) vs. 3.804% (+/- 0.7839, p=0.0594) and 88.91 (+/- 5.978) MFI vs. 115.2 MFI (+/- 
10.40, p= 0.0348).  HVEM expression was 90.27% (+/- 1.335) vs. 94.60% (+/- 1.335, 
p=0.1083) and1056 MFI (+/- 60.30) vs. 1405 (+/- 116.8, p= 0.0115). LIGHT expression was 
6.967% (+/- 1.703)) vs. 14.53% (+/- 3.915, p=0.0846) and 124.9 MFI (+/- 9.757) vs. 160.6 
(+/- 22.36, p= 0.1516). These results are summarized in Fig 4.2. 
In the CMV specific CD8+ group analysis of mean BTLA expression in GBM vs. controls 
was 5.150% (SEM +/- 1.756) vs. 2.329% (+/- 0.7465, p=0.1163) and 90.68 (+/- 17.56) MFI 
vs. 91.97 MFI (+/- 9.603, p= 0.9447).  HVEM expression was 92.80% (+/- 3.259) vs. 93.81% 
(+/- 1.693, p=0.7648) and 964.5 MFI (+/- 82.47) vs. 1006 (+/- 87.37, p= 0.7605). LIGHT 
expression was 70.60% (+/- 5.742) vs. 69.10% (+/- 7.251, p=0.8912) and 153.8 MFI (+/- 
18.87) vs. 195.4 (+/- 48.21, p= 0.5474). These results are summarized in Fig 4.3. 
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Fig 4.3: Analysis of BTLA, LIGHT and HVEM expression in CD8+ T-Cells. A represenative 
analysis of FACS gating for CMV Specific CD8+ T-Cells demonstrating expression of BLTA, 
LIGHT and HVEM including FMO controls. 
 
   73 
 
H
ea
lth
y
G
B
M
0
5
10
15
%
 B
T
L
A
+
 o
f 
 C
D
8
+ p = 0.05940
H
ea
lt
hy
G
B
M
0
50
100
150
200
250
M
F
I 
fo
r 
B
T
L
A
 i
n
 C
D
8
+
p = 0.03475
H
ea
lt
hy
G
B
M
50
60
70
80
90
100
110
%
 H
V
E
M
+
 o
f 
C
D
8
+
p = 0.1083
H
ea
lt
hy
G
B
M
0
500
1000
1500
2000
2500
M
F
I 
o
f 
H
V
E
M
 i
n
 C
D
8
+ p = 0.01152
H
ea
lt
hy
G
B
M
0
20
40
60
80
%
 L
IG
H
T
+
v
e
 o
f 
C
D
8
+
p = 0.08458
H
ea
lt
hy
G
B
M
0
200
400
600
M
F
I 
o
f 
L
IG
H
T
 i
n
 C
D
8
+
p = 0.1516
 
Fig 4.4:  T-Cell Expression of BTLA, HVEM and LIGHT. Plot of % and median flurecent 
intencity (MFI) of total CD8+ cells expressing BTLA, HVEM and  LIGHT . 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 Fig 4.5:  CMV Specific T-Cell Expression of BTLA, HVEM and LIGHT. Plot of  % and 
MFI of CMV specific CD8+ cells expressing BTLA, HVEM and LIGHT.  
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Immunohistochemistry 
15 tumour samples were stained for HVEM.  HVEM expression was seen in malignant cells 
in 6 of the 15 samples as shown in Table 4.2. In all samples lymphocytes were identified and 
assessed separately from the malignant tumour cells, however in only 1 specimen HVEM 
staining was seen and this was not included in this analysis. The distribution of staining 
analysis was all cytoplasmic in nature.  Some intra-nuclear staining was seen but this was 
thought to be artefact and not included as a positive result. Also membrane staining was seen 
in only one sample and therefore not thought to be reliable and not included for analysis. 
 
Table 4.1: HVEM Expression in GBM by Immunohistochemistry 
HVEM Expression None 1 2 3 
Number of Tumours (n=15) 9 2 3 1 
Percentage of Tumours 60% 13% 20% 7% 
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Fig 4.6: Immunohisotchemical staining for HVEM in GBM.  Slides showing garding scale of  immunohisotchemical staining for HVEM  in  
GBM tissue.  A) Normal Brain with no staining., B) Grade 1, C) Grade 2 and D) Grade 3.  
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4.4. Discussion 
These results demonstrate that in total and CMV specific CD8+ T-Cells isolated from the 
peripheral circulation there are no significant differences in surface expression of 
BTLA/LIGHT and HVEM between healthy controls and patients with GBM.  
There was significantly greater expression of BTLA and HVEM on total CD8+ T-cells in 
healthy controls compared to GBM patients in MFI, which in the case of HVEM, was not 
confirmed in terms of % of cells expressing that molecule. This was also at odds with the 
results of the gene expression analysis which showed greater expression of BTLA in GBM 
patients’ compared to healthy controls. This result therefore should be treated with some 
scepticism.  
The lack of difference between the GBM and control group in this study suggests that the 
HVEM pathway may be unimportant in immuno-evasion by the tumour. Certainly it would 
suggest that it may not be involved in the systemic immunosuppression seen in GBM 
patients. There is however plausible reasons that could mask a potential active role in 
immunosuppression in GBM patients.   
In the early phase of acute infection BTLA is expressed at high levels in CMV specific T-
Cells with associated inhibition of function [192]. As the infection moves towards a chronic 
state the long term effector cells become largely BTLA negative [190]. In the chronic disease 
setting of persistent viral infection BTLA is down regulated. However recent studies have 
shown BTLA expression persisting in the T-cells of patients with melanoma [190]. In 
comparing Total CD8+ T-cells we are mainly comparing a mixed group of naive and effector 
T-cells rather than a subgroup which has been activated by tumour or disease and therefore 
we would expect more uniform high expression of BTLA and any changes in the gene 
expression may require cell activation before becoming apparent in surface expression. 
These results do not support the suggestion that BTLA/LIGHT/HVEM pathway is important 
in immune suppression by GBM. However to fully explore these possibilities discussed 
above these studies could be repeated using CD8+ cells isolated from tumour samples. 
Results from samples taken from a single patient post adoptive T-cell transfer showed that 
expression of a number of markers such as PD-1, TIM-3, CTLA, T-bet, EOMES and LEF-1 
were different in tumour infiltrating cells compared to PBMC’s taken at similar time points 
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[193]. This suggests differences may exist between peripheral CD8+ T-cells in these patients 
and the TIL’s within GBM tissue.  
The immunohistochemical staining of GBM tissue showed expression in a third of tumours 
studied. Immunohistochemistry as a technique has many limitations which may result in false 
or artefact signal. In this case the presence of intra-nuclear staining was seen and though to be 
artefact as the more expected staining pattern would be cytoplasmic and on the cell 
membrane. Furthermore the small number of samples used in this study precludes any 
meaningful analysis of the true extent of expression in GBM tissue and relation of this to 
clinical effects such as impact of expression of HVEM on survival. While expression of 
HVEM was only seen in a third of samples studied nonetheless the presence of HVEM 
expression in some GBM suggests it may play a role in the biology of the tumour.  
 
Key Points: 
• In CMV Specific CD8+ T-Cells there is no difference between GBM patients and 
Controls in expression of BTLA, LIGHT and HVEM. 
• In the total CD8+ T-cells of GBM patients there is significantly less expression of 
BTLA and HVEM in GBM patients compared to controls.  
• HVEM is expressed in some GBM tissue; this supports the potential role of the 
HVEM/LIGHT/BTLA pathway in creating immunosuppression in the tumour micro-
environment. 
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Chapter 5: Discussion 
The aim of these studies was to further functionally characterise cytotoxic T-cell and HCMV-
specific T-cell responses in GBM patients. The hope is that this will aid in characterising the 
relationship between the host immune response and the progression of the disease with the 
ultimate goal being production of an effective adoptive T-cell therapy.   
The presence of HCMV in GBM is controversial but is gaining acceptance.  The impact of 
the presence of HCMV as a prognostic factor remains unresolved. Two recent studies have 
resulted in contradictory results [118, 119]. Both of these studies were based on analysis of 
HCMV products in tumour tissue. The aim of the study described in chapter 2 was to assess 
the effects of exposure to HCMV as measured by peripheral blood sample serology on 
outcome in GBM.  This test is readily available from simple serum samples and at small cost 
compared to analysis of tumour tissues. The data from this study demonstrates no difference 
in outcomes between those patients who have HCMV+ and HCMV– serology. These 
findings are supported in the existing literature [181].  
The impaired T-Cell response to malignancy is from multifactorial phenomena discussed in 
the introduction. The gene array analysis in this thesis provides an opportunity to identify 
potential mechanisms by which T-Cell function is impaired and define targets for further 
investigation. Measurement of the gene expression does not however give any information on 
the functional significance of these gene products. Also mRNA levels may not correlate to 
protein expression levels once posttranslational modifications have taken place. Nevertheless 
there were a large number of potential gene targets identified by this study all of which could 
potentially be examined in relation to impaired T-Cell function in the setting of GBM.  Given 
constraints of time on this thesis the BTLA and LIGHT were  chosen from the candidate 
genes identified for further analysis. These genes were chosen as these two molecules act on 
the same ligand and were shown to be altered in the total CD8+ population which in this 
study had the largest number of subjects’ thus more robust data. 
Analysis of  BTLA/LIGHT/HVEM expression with FACS analysis and 
immunohistochemistry did not clearly define an important role for this pathway in GBM 
patients. In the CMV specific T-cell population there was no significant difference in 
expression of these molecules. In the total CD8+ T-cell population expression of LIGHT was 
unchanged between GBM and the control subjects. There was increased expression of BTLA 
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and HVEM in controls compared to GBM which was the opposite of the expected result from 
the gene expression analysis. This difference was seen in both % counts and MFI for BTLA 
but only in the MFI analysis for HVEM. It may be that activation of the T-cells may be 
required to see the full changes in gene expression on the surface expression of the molecule 
for which it codes due to post-translational modifications. If this were the case then 
stimulation of the cell, via an activation assay, may be required to see the changes in gene 
expression reflected in the surface expression in the T-Cell population.  
It may simply be that BTLA/LIGHT is important in immunosuppression in GBM but is only 
seen at the tumour microenvironment level. To evaluate if this is the case with 
BTLA/LIGHT/HVEM the current experiment could be repeated examining expression of 
these molecules in TILs rather than T-cells from PBMC’s. The difficulty with this approach 
is that TIL’s have to be harvested from tumour samples which remains an onerous procedure 
and requires immediate processing of tumour samples.  Alternative strategies may involve 
identification of a tumour specific marker and FACS cell sorting to isolate a tumour specific 
population from the peripheral circulation.  
While the results of the FACS analysis suggest a limited role for the BTLA/LIGHT/HVEM 
pathway in GBM immune evasion the immunohistochemistry did show expression of HVEM 
in tumour tissue which has not previously been reported. HVEM has been shown to be 
present in melanoma and proposed to act via a “trans” interaction with BTLA to inhibit T-
cell function. The presence of HVEM in this study means that this interaction is at least 
possible in GBM. Given limitations of this study discussed in the chapter these findings need 
to be replicated with further immunohistochemistry, tumour cell cultures or  flow cytometry 
of studies of tumour lysates. 
BTLA expression along with many other molecules such as PD-1 is believed to be a maker of 
the “exhaustion” in T-cells [71].  BTLA is expressed on naive T-cells but is down regulated 
by activation to effector cells. Interest in its role in malignancy has been sparked by the 
discovery of persistent expression of BTLA in tumour specific T-cells in melanoma. Recent 
studies have now provided conflicting evidence about the role of BTLA. In a mouse model of 
adaptive cell transfer, blockade of the HVEM pathway resulted in tumour size reduction 
[194]. This was presumed by blocking of the inhibitory signal from BTLA and allowing 
HVEM to solely be stimulatory in response to LIGHT. However, in a human melanoma 
adoptive cell therapy trial, BTLA expression was seen to be correlated with improved 
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response [195]. In fact there is evidence that BTLA may provide bidirectional signalling, 
playing different roles at different stages of T-cell differentiation.   
There are now suggestions that BTLA along with other markers such as PD-1 and Tims-3 are 
less co-inhibitory molecules rather markers of a state of T-cell activation where the cell is 
activated but not differentiated, an effector memory cell [196].  In this state the expression of 
these inhibitory molecules could be a mechanism to regulate the immune response and 
prevent harm. This argument has been supported in regard to PD-1 by gene expression 
studies in healthy donors where CD8+ T-cells with high PD-1 expression were seen to be 
phenotypically different from exhausted T-cells from HIV patients [197]. BTLA itself has not 
been seen to be part of the exhaustion gene signature in gene expression studies on tumour 
specific T-cells [198]. Instead these cells showed a phenotype similar to effector memory 
cells.  Thus in the tumour setting,CD8+ T-cells would be effector memory cells  activated by 
antigenic stimulation and the pro-inflammatory microenvironment but unable to differentiate 
due to an inhibitory cytokine milieu or lack of correct co-stimulation. 
In terms of impact for adoptive T-cell therapy it has been shown that ex vivo stimulation has 
been able to overcome high levels of expression of BTLA and generate anti-tumour response 
once transferred to patients [199]. The suggestion discussed above that the cell expressing these 
exhaustion markers are not exhausted but rather incompletely differentiated means that they 
may potentially prove to be a valuable sub-population for immunotherapy. If this sub-
population of cells can be targeted in a way to promote their continued differentiation to 
effector cells they may provide significant anti-tumour immunity. Indeed in TIL’s isolated from 
melanoma patients BTLA+ CD8+ cells had better proliferative response to stimulation with 
IL2 and persistence of T-cell clones in vivo compared to BTLA- CD8+ TIL’s [200]. The same 
group also co-cultured TIL’s with HVEM+ cells and observed improved survival through 
activation of the PI3K-Akt pathway. It was therefore suggested that BTLA+ T-cells provide  
both an inhibitory role to limit over stimulation and also promote cell survival via PI3K-Akt 
pathway. Thus this pathway provides an immune fine tuning system. 
Network analysis of the gene expression data shows a common convergence in both the 
CMV specific and Total T-cell population on the IL12 complex. Changes in the cytokine 
milieu within GBM has been well documented [90]. These cytokines act on multiple 
pathways to affect immune function with an important effect being the tipping of the immune 
environment toward the TH2 response [91].  IL 12 is of interest as it is a promoter of the more 
   82 
immunostimulatory TH1 response. Interaction with IL12 via the pathways suggested by this 
data supports that this cytokine could be important in potentiating tumour growth in GBM. 
Therefore targeting IL12 becomes an attractive  immunotherapy strategy to promote the TH1 
environment  and thus  potentiate the effects of adoptive cell or vaccine therapies [201].  
Immunotherapy for GBM appears a promising therapy as an adjunct to an overall treatment 
regime involving surgery, radiotherapy and chemotherapy [178].  The identification of 
HCMV in GBM tissue whilst of uncertain clinical significance does provide and attractive 
target for immunotherapy strategies such as adoptive T-cell therapy. Significant barriers to 
immunotherapy remain, some of which relate to the role of co-stimulatory and inhibitory 
molecules in host response to malignancy and this is currently an area of intense interest. The 
role of these various molecules in GBM is uncertain. However there is considerable potential 
for therapeutic manipulation of these pathways. The outcome of the experiments detailed in 
this thesis raise the possibility of the BTLA/LIGHT/HVEM pathway being of some 
importance in the setting of GBM. Unfortunately the exact role remains unclear. Further 
studies are required to define the role of these pathways and their suitability for manipulation 
as a standalone therapy or adjunct to other immunotherapeutic strategies. 
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Appendix: Genes included in Gene Expression Analysis  
 
Functional group Gene name Assay ID 
Cell Division and Metabolism BIRC5 Hs04194392_s1 
 CDCA7 Hs00230589_m1 
 CDK2 Hs01548894_m1 
 G0S2 Hs00274783_s1 
 MCM4 Hs00907398_m1 
 MKI67 Hs01032443_m1 
 SAP30 Hs01009154_g1 
 TYMS Hs00426586_m1 
 UHRF1 Hs01086727_m1 
   
Survival and Apoptosis BAD Hs00188930_m1 
 BAK1 Hs00832876_g1 
 BAX Hs00180269_m1 
 BCL2L1 Hs00236329_m1 
 BCL2L11 Hs00708019_s1 
 BIK Hs00154189_m1 
 CASP1 Hs00354836_m1 
 FAS Hs00236330_m1 
 FASLG Hs00181225_m1 
 MCL1 Hs01050896_m1 
 TNFSF10 Hs00921974_m1 
 TNFSF14 Hs00542477_m1 
 XAF1 Hs00213882_m1 
 XIAP Hs00745222_s1 
   
Effector Molecules GZMA Hs00989184_m1 
 GZMB Hs01554355_m1 
 GZMK Hs00157878_m1 
 PROK2 Hs01587689_m1 
 SPON2 Hs00202813_m1 
   
Transcription Factors BCL6 Hs00153368_m1 
 EOMES Hs00172872_m1 
 FOXP3 Hs01085834_m1 
 GATA3 Hs00231122_m1 
 LEF1 Hs01547250_m1 
 NR3C2 Hs01031809_m1 
 PRDM1 Hs00153357_m1 
 RORC Hs01076122_m1 
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 SCML1 Hs00232467_m1 
 SOCS3 Hs02330328_s1 
 TBX21 Hs00203436_m1 
 TSC22D3 Hs00608272_m1 
 ZNF395 Hs00608626_m1 
 ZNF683 Hs00543184_m1 
   
Migration and Adhesion ADAM8 Hs00174246_m1 
 CCR1 Hs00928897_s1 
 CCR5 Hs99999149_s1 
 CCR7 Hs01013469_m1 
 CXCR1 Hs01921207_s1 
 CXCR3 Hs01847760_s1 
 CXCR5 Hs00540548_s1 
 CX3CR1 Hs01922583_s1 
 ITGA6 Hs01041011_m1 
 ITGAD Hs00236178_m1 
 ITGAL Hs00158218_m1 
 ITGB1 Hs00559595_m1 
 ITGB2 Hs00164957_m1 
 SELL Hs00174151_m1 
   
Cytokine Receptors CXCR6 Hs01890898_s1 
 IL2RA Hs00907779_m1 
 IL2RB Hs01081697_m1 
 IL7R Hs00902334_m1 
 IL17RA Hs01064648_m1 
 IL18R1 Hs00977691_m1 
 IL28RA Hs00417120_m1 
   
Chemokines and Cytokines CCL4 Hs00605740_g1 
 CCL5 Hs00174575_m1 
 CXCL13 Hs00757930_m1 
 IFNG Hs00989291_m1 
 IL2 Hs00174114_m1 
 IL4 Hs00174122_m1 
 IL8 Hs00174103_m1 
 IL10 Hs00961622_m1 
 IL17A Hs00174383_m1 
 IL21 Hs00222327_m1 
 IL32 Hs00992441_m1 
 TGFB1 Hs00998133_m1 
   
Differentiation and Exhaustion BTLA Hs00699198_m1 
 CD27 Hs00386811_m1 
 CD28 Hs01007422_m1 
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 CD160 Hs00199894_m1 
 CD244 Hs00175568_m1 
 CD40LG Hs00163934_m1 
 CTLA4 Hs03044418_m1 
 HAVCR2 Hs00262170_m1 
 ICOS Hs00359999_m1 
 KLRC1 Hs00970273_g1 
 KLRD1 Hs00233844_m1 
 KLRG1 Hs00929964_m1 
 LAG3 Hs00158563_m1 
 PDCD1 Hs01550088_m1 
 PTGER2 Hs00168754_m1 
   
housekeeping genes 18S Hs99999901_s1 
 ACTB Hs01060665_g1 
 B2M Hs00984230_m1 
 
